<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9645116</article-id><article-id pub-id-type="pmcid-ver">PMC9645116.1</article-id><article-id pub-id-type="pmcaid">9645116</article-id><article-id pub-id-type="pmcaiid">9645116</article-id><article-id pub-id-type="pmid">36386185</article-id><article-id pub-id-type="doi">10.3389/fphar.2022.999300</article-id><article-id pub-id-type="publisher-id">999300</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Potential of nanoformulations in malaria treatment</article-title><alt-title alt-title-type="left-running-head">Chaves et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2022.999300" ext-link-type="uri">10.3389/fphar.2022.999300</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chaves</surname><given-names initials="JB">Janaina Braga</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Portugal Tavares de Moraes</surname><given-names initials="B">Bianca</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1130697/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Regina Ferrarini</surname><given-names initials="S">Stela</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>No&#233; da Fonseca</surname><given-names initials="F">Francisco</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silva</surname><given-names initials="AR">Adriana Ribeiro</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Gon&#231;alves-de-Albuquerque</surname><given-names initials="CF">Cassiano Felippe</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/517582/overview"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Immunopharmacology Laboratory</institution>, <institution>Department of Biochemistry</institution>, <institution>Federal University of the State of Rio de Janeiro&#8212;UNIRIO</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Pharmaceutical Nanotechnology Laboratory</institution>, <institution>Federal University of Mato Grosso of Sinop Campus&#8212;UFMT</institution>, <addr-line>Cuiab&#225;</addr-line>, <country>Brazil</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Empresa Brasileira de Pesquisa Agropecu&#225;ria</institution>, <institution>Parque Esta&#231;&#227;o Biol&#243;gica&#8212;PqEB</institution>, <institution>EMBRAPA</institution>, <addr-line>Bras&#237;lia</addr-line>, <country>Brazil</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Immunopharmacology Laboratory</institution>, <institution>Oswaldo Cruz Foundation, FIOCRUZ&#8212;UNIRIO</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1157173/overview" ext-link-type="uri">Rafael V. C. Guido</ext-link>, University of S&#227;o Paulo, Brazil</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/857460/overview" ext-link-type="uri">Raj Kumar</ext-link>, University of Nebraska Medical Center, United States</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1650094/overview" ext-link-type="uri">Prashanth K. B. Nagesh</ext-link>, Memorial Sloan Kettering Cancer Center, United States</p></fn><corresp id="c001">*Correspondence: Cassiano Felippe Gon&#231;alves-de-Albuquerque, <email>cassiano.albuquerque@unirio.br</email></corresp><fn fn-type="other"><p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>10</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">400058</issue-id><elocation-id>999300</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2022</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>10</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>15</day><month>11</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-06 09:25:35.633"><day>06</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Chaves, Portugal Tavares de Moraes, Regina Ferrarini, No&#233; da Fonseca, Silva and Gon&#231;alves-de-Albuquerque.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Chaves, Portugal Tavares de Moraes, Regina Ferrarini, No&#233; da Fonseca, Silva and Gon&#231;alves-de-Albuquerque</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-13-999300.pdf"/><abstract><p>Malaria is caused by the protozoan <italic toggle="yes">Plasmodium sp</italic> and affects millions of people worldwide. Its clinical form ranges from asymptomatic to potentially fatal and severe. Current treatments include single drugs such as chloroquine, lumefantrine, primaquine, or in combination with artemisinin or its derivatives. Resistance to antimalarial drugs has increased; therefore, there is an urgent need to diversify therapeutic approaches. The disease cycle is influenced by biological, social, and anthropological factors. This longevity and complexity contributes to the records of drug resistance, where further studies and proposals for new therapeutic formulations are needed for successful treatment of malaria. Nanotechnology is promising for drug development. Preclinical formulations with antimalarial agents have shown positive results, but only a few have progressed to clinical phase. Therefore, studies focusing on the development and evaluation of antimalarial formulations should be encouraged because of their enormous therapeutic potential.</p></abstract><kwd-group><kwd>malaria</kwd><kwd>treatment</kwd><kwd>pre-clinical study</kwd><kwd>nanotechnology</kwd><kwd>infectious disease</kwd></kwd-group><funding-group><award-group><funding-source id="cn003"><institution-wrap><institution>Funda&#231;&#227;o Carlos Chagas Filho de Amparo &#224; Pesquisa do Estado do Rio de Janeiro
</institution><institution-id institution-id-type="doi">10.13039/501100004586</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn003">26/010.000983/2019 E-26/203.290/2017 E-26/2010.592/2019 E-26/201.448/2021</award-id></award-group><award-group><funding-source id="cn006"><institution-wrap><institution>FP7 Ideas: European Research Council
</institution><institution-id institution-id-type="doi">10.13039/100011199</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn006">HEALTH-F4-2011-282095</award-id></award-group><award-group><funding-source id="cn001"><institution-wrap><institution>Universidade Federal Fluminense
</institution><institution-id institution-id-type="doi">10.13039/501100010435</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior
</institution><institution-id institution-id-type="doi">10.13039/501100002322</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn004"><institution-wrap><institution>Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico
</institution><institution-id institution-id-type="doi">10.13039/501100003593</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn005"><institution-wrap><institution>Funda&#231;&#227;o Oswaldo Cruz
</institution><institution-id institution-id-type="doi">10.13039/501100006507</institution-id></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Malaria is a disease that affected 241 million people and led to 627,000 deaths worldwide in 2020. It is considered a significant public health problem that preferentially occurs in tropical and subtropical regions and is an endemic disease in 85 countries (<xref rid="B115" ref-type="bibr">World malaria report, 2021</xref>).</p><p>The incidence of malaria occurs in an environment conducive to the spread of the vector mosquito, geographically in developing and underdeveloped countries. Among the 85 countries reporting malaria cases in 2020, 29 accounted for 96% of malaria cases worldwide, and six countries in the African continent accounted for 55% of global malaria incidence. Malaria mortality rate (deaths per 100,000 inhabitants at risk) decreased from 30% in 2000 to 15% in 2015 and to 13% in 2019. However, in 2020, the mortality rate increased to 15%. The increased mortality rate of malaria in 2020 was associated with the interruption of medical services for malaria treatment due to COVID-19 pandemic (<xref rid="B115" ref-type="bibr">World malaria report, 2021</xref>).</p><p>The causative agent of malaria is the protozoan <italic toggle="yes">Plasmodium sp</italic>, which is inoculated into the human body by mosquitoes of the genus <italic toggle="yes">Anopheles</italic> during hematophagy. There is a complex mosquito-human-parasite cycle, and five species of the parasite can infect humans: <italic toggle="yes">Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi</italic> (<xref rid="B91" ref-type="bibr">Phillips et al., 2017</xref>; <xref rid="B12" ref-type="bibr">Ashley et al., 2018</xref>). Clinical manifestation of the disease in humans occurs due to the pre-programmed biology of the parasite in conjunction with the human pathophysiological response (<xref rid="B74" ref-type="bibr">Milner, 2018</xref>; <xref rid="B63" ref-type="bibr">Knackstedt et al., 2019</xref>). Two distinct stages occur in the life cycle of <italic toggle="yes">Plasmodium sp</italic>: sexual cycle in the vector mosquito and asexual cycle in the human host (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Life cycle of <italic toggle="yes">Plasmodium</italic> sp. The cycle can be divided into two stages: mosquito vector or sexual cycle and human host or asexual cycle. The mosquito ingests gametocytes while performing hematophagy. The zygote is formed from the union of gametocytes and generates oocyte. It crosses the intestinal wall and forms oocyst that releases sporozoites, which migrate to the mosquito&#8217;s salivary glands, completing the sexual cycle. The infected female <italic toggle="yes">Anopheles sp</italic> mosquito inoculates sporozoites, performs hematophagy, and begins the asexual cycle of <italic toggle="yes">Plasmodium sp</italic> in human. Sporozoites are transported to the liver through the blood, and asexual multiplication occurs in the hepatocytes, forming merozoites in the pre-erythrocytic cycle (<xref rid="B12" ref-type="bibr">Ashley et al., 2018</xref>). In <italic toggle="yes">P. vivax</italic> and <italic toggle="yes">P. ovale</italic> infections, some sporozoites differentiate in the liver to a latent form called hypnozoites. After rupture of the hepatocytes, merozoites are released into the bloodstream and penetrate the erythrocytes (erythrocyte phase), assuming a ring-shaped configuration (<xref rid="B30" ref-type="bibr">Coban et al., 2018</xref>). Proliferative schizogony occurs in infected erythrocytes, where merozoites multiply asexually, differentiating into schizonts and trophozoites. Erythrocytes rupture and release schizonts into the bloodstream, where one part differentiates into male and female gametocytes, and another part infects new erythrocytes (<xref rid="B91" ref-type="bibr">Phillips et al., 2017</xref>; <xref rid="B12" ref-type="bibr">Ashley et al., 2018</xref>). Image was created in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-999300-g001.jpg"/></fig></sec><sec id="s2"><title>Pathophysiology</title><p>The pathogenesis of malaria is related to the blood cycle. Symptoms usually appear approximately 10&#8211;15&#160;days after infection, and the disease evolves with febrile response and potentially progresses to severe malaria, which is a consequence of parasite multiplication and invasion of red blood cells by parasites (<xref rid="B80" ref-type="bibr">Najer et al., 2018</xref>; <xref rid="B63" ref-type="bibr">Knackstedt et al., 2019</xref>). Malaria can be classified as asymptomatic, uncomplicated, and severe (<xref rid="B117" ref-type="bibr">World malaria report, 2020</xref>). Any <italic toggle="yes">Plasmodium sp</italic> can cause asymptomatic malaria (<xref rid="B21" ref-type="bibr">Brazier et al., 2017</xref>) or uncomplicated malaria, which is manifested as chills, sweating, headache, nausea, or vomiting without severe organ dysfunction (<xref rid="B91" ref-type="bibr">Phillips et al., 2017</xref>; <xref rid="B77" ref-type="bibr">Moxon et al., 2020</xref>). <italic toggle="yes">P. falciparum</italic> causes the most severe malaria disease, with severe organ damage, anemia, and hyperparasitemia (<xref rid="B21" ref-type="bibr">Brazier et al., 2017</xref>; <xref rid="B77" ref-type="bibr">Moxon et al., 2020</xref>).</p><p>Disruption of <italic toggle="yes">Plasmodium sp</italic>-infected erythrocytes leads to the release of malaria parasites and endotoxins, a complex of parasite DNA and hemozoin (<xref rid="B21" ref-type="bibr">Brazier et al., 2017</xref>; <xref rid="B12" ref-type="bibr">Ashley et al., 2018</xref>). Endotoxins are recognized by immune cells through Toll-like receptor 9 (TLR9), which increases the production of cytokines and chemokines (<xref rid="B57" ref-type="bibr">Karunaweera et al., 1992</xref>; <xref rid="B79" ref-type="bibr">Mubaraki et al., 2017</xref>). Oxidative stress increases the inflammatory response by releasing cytokines that cause organ damage (<xref rid="B41" ref-type="bibr">Dunst et al., 2017</xref>; <xref rid="B60" ref-type="bibr">Katsoulis et al., 2021</xref>). The membrane of erythrocytes infected by parasites hardens and loses its standard shape, contributing to the obstruction of capillaries and thrombus formation. Consequently, when vital organs are affected, severe malaria progresses to death (<xref rid="B30" ref-type="bibr">Coban et al., 2018</xref>; <xref rid="B62" ref-type="bibr">Klinkhamhom et al., 2020</xref>).</p><sec id="s2-1"><title>Malaria treatment recommended by World Health Organization</title><p>The first- and second-line of treatment recommended by the World Health Organization (WHO) for uncomplicated <italic toggle="yes">P. falciparum</italic> malaria and chloroquine-resistant <italic toggle="yes">P. vivax</italic> is artemisinin-based combination therapies (ACTs) (<xref rid="B97" ref-type="bibr">Report on antimalarial drug efficacy, 2020</xref>; <xref rid="B117" ref-type="bibr">World malaria report, 2020</xref>). This therapy combines an artemisinin derivative with a partner drug. Artemisinin compound plays an important role in reducing the number of parasites during the first 3&#160;days of treatment. After this period, the partner drug eliminates the remaining parasites (<xref rid="B97" ref-type="bibr">Report on antimalarial drug efficacy, 2020</xref>).</p><p>Currently, several drugs that act during different stages of the parasite&#8217;s biological cycle are available for malaria prevention and cure (<xref rid="F2" ref-type="fig">Figure 2</xref>). Most antimalarial agents target erythrocytic and asexual stages (<xref rid="B17" ref-type="bibr">Belete, 2020</xref>; <xref rid="B66" ref-type="bibr">Madhav and Hoda, 2021</xref>). Tafenoquine and primaquine are approved antimalarial agents against parasites and hypnozoites at the hepatic stage (<xref rid="B108" ref-type="bibr">Thriemer et al., 2017</xref>; <xref rid="B31" ref-type="bibr">Commons Id et al., 2019</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Current drug targets for malaria treatment: I&#8212;Asexual cycle; II&#8212;Liver cycle, III, IV, VI&#8212;Erythrocytic cycle, V&#8212;Asexual and sexual cycles. Source: Artemisinin-based combination therapies (ACTs) are recommended by the World Health Organization (<xref rid="B117" ref-type="bibr">World malaria report, 2020</xref>; <xref rid="B118" ref-type="bibr">Wicht et al., 2020</xref>; <xref rid="B115" ref-type="bibr">World malaria report, 2021</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-999300-g002.jpg"/></fig><p>The WHO currently recommends six ACTs as the first- and second-line of treatment for uncomplicated cases (<xref rid="T1" ref-type="table">Table 1</xref>). In regions where malaria transmission is moderate to high, the WHO recommends intermittent preventive treatment in pregnancy (IPTp) during consultation from the beginning of the second trimester of pregnancy (<xref rid="T2" ref-type="table">Table 2</xref>) (Report on antimalarial drug efficacy, 2020).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>WHO-recommended artemisinin-based combination therapies (ACTs).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P. falciparum</italic> (uncomplicated)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P. vivax</italic> (uncomplicated)</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Artemether-lumefantrine (AL)</td><td align="left" rowspan="1" colspan="1">Chloroquine (CQ)</td></tr><tr><td align="left" rowspan="1" colspan="1">Artesunate-amodiaquine (AS-AQ)</td><td rowspan="5" align="left" colspan="1">ACTs in areas with CQ resistance</td></tr><tr><td align="left" rowspan="1" colspan="1">Artesunate-mefloquine (AS-MQ)</td></tr><tr><td align="left" rowspan="1" colspan="1">Artesunate-pyronaridine (AS-PY)</td></tr><tr><td align="left" rowspan="1" colspan="1">Artesunate + sulfadoxine-pyrimethamine (AS + SP)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dihydroartemisinin-piperaquine (DHA-PPQ)</td></tr></tbody></table><table-wrap-foot><fn><p>Source: Adapted from Report on Antimalarial Drug Efficacy, Resistance and Response: 10&#160;years of Surveillance (Report on antimalarial drug efficacy, 2020; <xref rid="B117" ref-type="bibr">World malaria report, 2020</xref>).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>WHO-recommended treatment for uncomplicated malaria in pregnant woman.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th colspan="2" align="left" rowspan="1">
<italic toggle="yes">P. falciparum</italic>
</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" rowspan="1">&#8195;Not complicated</td><td align="left" rowspan="1" colspan="1">ACT</td></tr><tr><td colspan="2" align="left" rowspan="1">&#8195;First, second, and third-trimester of pregnancy</td><td align="left" rowspan="1" colspan="1">Quinine + clindamycin ACT</td></tr><tr><td colspan="2" align="left" rowspan="1">
<italic toggle="yes">P. vivax, P. ovale, P. malarie, P. knowlesi</italic>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" align="left" colspan="1">&#8195;Blood stage</td><td align="left" rowspan="1" colspan="1">Not complicated</td><td align="left" rowspan="1" colspan="1">Chloroquine or ACT</td></tr><tr><td align="left" rowspan="1" colspan="1">1st-trimester pregnant women</td><td align="left" rowspan="1" colspan="1">Chloroquine or quinine</td></tr><tr><td align="left" rowspan="1" colspan="1">2nd trimester</td><td align="left" rowspan="1" colspan="1">Chloroquine or ACT</td></tr><tr><td colspan="2" align="left" rowspan="1">&#8195;Liver stage ( <italic toggle="yes">P. ovale/P. vivax</italic> )</td><td align="left" rowspan="1" colspan="1">Primaquine<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>Source: Adapted from Report on Antimalarial Drug Efficacy, Resistance and Response: 10&#160;years of Surveillance (Report on antimalarial drug efficacy, 2020; <xref rid="B117" ref-type="bibr">World malaria report, 2020</xref>).</p></fn><fn id="Tfn1"><label>
<sup>a</sup>
</label><p>Not recommended for children &lt;6 months, pregnant women, nursing mothers, or those with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3"><title>Resistance to antimalarials</title><p>Over the years, several endemic areas worldwide have reported increased incidence of <italic toggle="yes">Plasmodium</italic> drug resistance. Increasing drug resistance of <italic toggle="yes">Plasmodium sp</italic> is one of the main factors responsible for treatment failure (<xref rid="B93" ref-type="bibr">Rai et al., 2017</xref>; <xref rid="B65" ref-type="bibr">L-QuraishAy et al., 2020</xref>). In addition, the use of drugs from the same chemical family or having a similar mode of action may have intensified cross-resistance to antimalarial drugs (<xref rid="B26" ref-type="bibr">Capela et al., 2019</xref>; <xref rid="B110" ref-type="bibr">Tse et al., 2019</xref>).</p><p>Several studies have reported that molecular mechanisms of resistance to antimalarial drugs occur in several species of parasites and include polymorphisms in proteins that alter the physiological regulation in the parasite (<xref rid="B70" ref-type="bibr">Menard and Dondorp, 2017</xref>; <xref rid="B118" ref-type="bibr">Wicht et al., 2020</xref>). The occurrence of polymorphisms makes it obvious that resistance to antimalarial drugs is associated with the genetic factors of parasites. Single, double, or quadruple mutations in different genes confer resistance in the parasite to antimalarial drugs. For example, mutations in the <italic toggle="yes">Pfmdr1, Pfcrt, Pfmrp,</italic> and <italic toggle="yes">Pfnhe1</italic> genes confer drug resistance (<xref rid="B33" ref-type="bibr">Cubides et al., 2018</xref>; <xref rid="B50" ref-type="bibr">WWARN K13 Genotype-Phenotype Study Group, 2019</xref>).</p><p>Mutations in the <italic toggle="yes">Pfmdr1</italic> membrane transporter found in <italic toggle="yes">Plasmodium sp</italic> digestive vacuoles may influence parasite susceptibility to chloroquine (<xref rid="B91" ref-type="bibr">Phillips et al., 2017</xref>; <xref rid="B22" ref-type="bibr">Bree and levy, 2018</xref>). The <italic toggle="yes">Pfcrt</italic> and <italic toggle="yes">Pfmdr1</italic> are vital multidrug resistance proteins. The <italic toggle="yes">Pfmdr1</italic> encodes a p-glycoprotein homolog that affects sensitivity to multiple antimalarial drugs (<xref rid="B99" ref-type="bibr">Ross et al., 2018</xref>; <xref rid="B121" ref-type="bibr">Xu et al., 2018</xref>) including artemisinin, mefloquine, lumefantrine, quinine, and chloroquine (<xref rid="B89" ref-type="bibr">Patel et al., 2017</xref>; <xref rid="B121" ref-type="bibr">Xu et al., 2018</xref>). Atovaquone is a synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovaquone interferes with DNA synthesis by blocking mitochondrial transport of electrons from the protozoan respiratory chain, leading to cell death (<xref rid="B105" ref-type="bibr">Staines et al., 2018</xref>; <xref rid="B59" ref-type="bibr">Kathpalia et al., 2020</xref>). Unique mutations in the P<italic toggle="yes">fcytb</italic> gene of <italic toggle="yes">P. falciparum</italic> caused resistance to atovaquone in <italic toggle="yes">in vitro/in vivo</italic> experiments (<xref rid="B105" ref-type="bibr">Staines et al., 2018</xref>; <xref rid="B59" ref-type="bibr">Kathpalia et al., 2020</xref>). The gene encoding <italic toggle="yes">P. falciparum</italic> Kelch 13 (<italic toggle="yes">PfKelch13</italic>) has been identified as a genetic determinant of resistance (<xref rid="B22" ref-type="bibr">Bree and levy, 2018</xref>; <xref rid="B50" ref-type="bibr">WWARN K13 Genotype-Phenotype Study Group, 2019</xref>). K13 mutations reduce protein function and cause artemisinin resistance by reducing its activation (<xref rid="B107" ref-type="bibr">Talman et al., 2019</xref>; <xref rid="B118" ref-type="bibr">Wicht et al., 2020</xref>).</p><p>All molecular targets of antimalarial drugs have not been defined. Drug resistance can occur via several pathways, such as processes that reduce drug toxicity, some catalytic processes that promote changes in enzyme reactions, or amplification of the gene encoding the target enzyme or transporter that pumps the drug out of the parasite (<xref rid="B99" ref-type="bibr">Ross et al., 2018</xref>; <xref rid="B37" ref-type="bibr">Deda et al., 2020</xref>). Surveillance of resistance to antimalarials is performed using three complementary approaches: 1) <italic toggle="yes">in vivo</italic> studies to evaluate the efficacy of medications in patients, 2) <italic toggle="yes">in vitro</italic> studies to assess the parasite susceptibility to medicinal products, and 3) molecular studies to detect genetic mutations and/or gene copy number alterations associated with drug resistance (<xref rid="B121" ref-type="bibr">Xu et al., 2018</xref>; <xref rid="B85" ref-type="bibr">Nsanzabana, 2019</xref>; <xref rid="B97" ref-type="bibr">Report on antimalarial drug efficacy, 2020</xref>). Many studies have described factors that indicate resistance to most drugs used to treat malaria and reveal possible targets for new drugs. With the advancement of molecular biology, metabolomics and proteomics details of the parasite support the development of new pharmacological agents such as nanopharmaceuticals. The work between academic research and pharmaceutical industry is essential and positive for treating malaria cases in endemic regions with efficient and technically targeted approaches.</p><sec id="s3-1"><title>Disadvantages of conventional antimalarials</title><p>The most evident disadvantage of conventional antimalarial drugs is <italic toggle="yes">Plasmodium sp</italic> resistance due to genetic polymorphisms (<xref rid="B22" ref-type="bibr">Bree and levy, 2018</xref>; <xref rid="B118" ref-type="bibr">Wicht et al., 2020</xref>). However, other disadvantages that influence malaria treatment with conventional antimalarial drugs include low water solubility, low bioavailability, side effects, and relatively short half-life (<xref rid="B8" ref-type="bibr">Alven and Aderibigbe, 2020</xref>; <xref rid="B96" ref-type="bibr">Rashidzadeh et al., 2021</xref>; <xref rid="B104" ref-type="bibr">Souza Botelho et al., 2021</xref>). Side effects frequently related to conventional antimalarial drugs include abdominal pain and gastrointestinal symptoms such as vomiting, jaundice, itching, hypoglycemia, anemia, dizziness, coma, and altered consciousness (<xref rid="B84" ref-type="bibr">Novitt-Moreno et al., 2021</xref>; <xref rid="B96" ref-type="bibr">Rashidzadeh et al., 2021</xref>). In addition, during prolonged use, there is a risk of hemolysis (tafenoquine and primaquine), retinopathy, mental confusion, cardiac complications (tafenoquine and chloroquine) (<xref rid="B84" ref-type="bibr">Novitt-Moreno et al., 2021</xref>), and gastric irritation (primaquine) (<xref rid="B34" ref-type="bibr">da Silva de Barros et al., 2021</xref>). Skin hypersensitivity reactions to sulfadoxine-pyrimethamine (Stevens-Johnson syndrome), severe hepatoxicity, and neuropsychiatric reactions to mefloquine have also been reported (<xref rid="B45" ref-type="bibr">Frey et al., 2010</xref>; <xref rid="B11" ref-type="bibr">Ashley and Phyo, 2018</xref>). In many cases, serious side effects resulted in treatment discontinuation (<xref rid="B23" ref-type="bibr">Brito-Sousa et al., 2019</xref>; <xref rid="B125" ref-type="bibr">Who, 2019</xref>).</p></sec><sec id="s3-2"><title>Development of new drugs/pharmaceuticals</title><p>Metabolic pathways, such as nucleic acid synthesis, heme detoxification, oxidative fatty acid synthesis, and stress, are the primary targets for development of new drugs (<xref rid="B16" ref-type="bibr">Baruah et al., 2017</xref>; <xref rid="B87" ref-type="bibr">Oyelade et al., 2019</xref>). In the search for new treatments, pharmaceutical companies have studied a variety of drug candidates for malaria control and elimination (<xref rid="B17" ref-type="bibr">Belete, 2020</xref>). New agents such as arterolane, cipargamin, and KAF156 have the potential to replace ACTs that fail to treat malaria infection. Therefore, there is an urgent need to reassess the current combination therapy for malaria treatment (<xref rid="B11" ref-type="bibr">Ashley and Phyo, 2018</xref>; <xref rid="B78" ref-type="bibr">Moyo et al., 2020</xref>).</p><p>To develop antiparasitic molecules, phenotypic screening studies of the parasite are essential (<xref rid="B32" ref-type="bibr">Cowell and Winzeler, 2019</xref>; <xref rid="B122" ref-type="bibr">Yahiya et al., 2019</xref>). In addition, phenotypic screening for the entire biological cycle of <italic toggle="yes">Plasmodium</italic> sp is needed to gather data in chemical libraries and enable discovery of multiple substances that have potential as antimalarials (<xref rid="B32" ref-type="bibr">Cowell and Winzeler, 2019</xref>; <xref rid="B122" ref-type="bibr">Yahiya et al., 2019</xref>).</p><p>Kae609, KAF156, DSM265, and MMV048 are the four most advanced antimalarials have emerged from multidisciplinary collaboration and are currently in phase II trials. The main objective of malaria treatment and elimination strategies is to target multiple stages of the parasite cycle (<xref rid="B106" ref-type="bibr">Summers et al., 2021</xref>). Combined antimalarial treatments that do not present artemisinin (ART) are recommended by the WHO when unavailable or suitable for treatment (<xref rid="B116" ref-type="bibr">Who, 2015</xref>). An open randomized phase III clinical study compared the efficacy of quinine/clindamycin with artemether/lumefantrine in treating uncomplicated malaria in children below 5&#160;years of age and did not find evidence for the use of quinine/clindamycin when artemether/lumefantrine is still effective (<xref rid="B86" ref-type="bibr">Obonyo et al., 2022</xref>). A single monthly prophylactic antimalarial drug composed of a combination of naphthoquinone-azithromycin (NQAZ) was used in a randomized, placebo-controlled, double-blind study to evaluate its protective effect against <italic toggle="yes">Plasmodium</italic> infection. Treatment with NQAZ showed 93.62% protective efficacy with a 95% confidence interval [CI] of 91.72&#8211;95.52 (<xref rid="B123" ref-type="bibr">Yang et al., 2021</xref>). A two-group, multicenter, and randomized comparative study compared the efficacy of a dispersible tablet composed of a combination of a fixed dose of arterolane maleate (AM) 37.5&#160;mg and piperaquine phosphate (PQP) 187.5&#160;mg and that of artemether-lumefantrine (AL) in pediatric patients with <italic toggle="yes">P. falciparum</italic> infection. Both treatments were considered safe with good tolerance, and the efficacy of the AM-PQP combination was compared to that of AL (<xref rid="B109" ref-type="bibr">Toure et al., 2016</xref>). There is an urgent need to develop rapid action antimalarials that act during the asexual stage in the blood to reduce the propensity to generate resistance. The four most successful antimalarials primarily target multiple stages of the malaria parasite&#8217;s life cycle (<xref rid="B13" ref-type="bibr">Ashton et al., 2019</xref>).</p></sec><sec id="s3-3"><title>Potential of nanotechnology in malaria</title><p>Recent studies have demonstrated the potential of nanotechnology for the treatment of different diseases through multiple techniques (<xref rid="F3" ref-type="fig">Figure 3</xref>). Nanostructured drug delivery systems have clinical applications in the treatment of immunological disorders such as allergy, cancer, arteriosclerosis, diabetes, and malaria (<xref rid="B24" ref-type="bibr">Calder&#243; et al., 2017</xref>; <xref rid="B27" ref-type="bibr">Charlie-Silva et al., 2018</xref>). FDA have already approved nanotherapies for a variety of applications, but at the best of our knowledge, none yet for malaria treatment (<xref rid="B75" ref-type="bibr">Mitchell et al., 2021</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Classes of Nanoparticles. Nanoparticles can be divided into organic (lipid-based and polymeric) and inorganic. Each class embodies several NPs with the most relevant highlighted in the figure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-999300-g003.jpg"/></fig><p>A considerable improvement in the pharmacokinetics and efficiency of the encapsulated nano drug was observed compared with that of the encapsulated free drug (<xref rid="B2" ref-type="bibr">Abdolmaleki et al., 2021</xref>; <xref rid="B18" ref-type="bibr">Biosca et al., 2021</xref>). Critical studies based on nanotechnology for the development of antimalarial drugs are aimed to solve key problem in malaria treatment, such as disease severity, and are focused on reduced level of drug toxicity, interruption of transmission of <italic toggle="yes">Plasmodium sp</italic>, increased efficacy of drugs, and mainly, combating multidrug resistance (<xref rid="B67" ref-type="bibr">Manconi et al., 2019</xref>; <xref rid="B82" ref-type="bibr">Nnamani et al., 2021</xref>). The use of nanostructured drug delivery systems can potentially solve the critical issue of <italic toggle="yes">Plasmodium sp</italic> multidrug resistance to drugs used for a long time in endemic regions, offering a new possibility of using the same drugs at manometric concentrations with reduced side effects (<xref rid="B69" ref-type="bibr">Marwah et al., 2020</xref>; <xref rid="B42" ref-type="bibr">Elmi et al., 2021</xref>).</p><p>Targeting a drug to unveil its precise mechanism of action is a crucial strategy for treating malaria. Several barriers must be eliminated to allow the drug to reach the intracellular parasite. Bioavailability, concentration, and elimination of drugs are important factors that need to be considered for successful treatment. Nanopharmaceuticals have a promising prospect (<xref rid="B88" ref-type="bibr">Panzarini et al., 2018</xref>; <xref rid="B5" ref-type="bibr">Akpa et al., 2020</xref>; <xref rid="B90" ref-type="bibr">Pestehchian et al., 2020</xref>; <xref rid="B124" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B51" ref-type="bibr">Guo et al., 2021</xref>; <xref rid="B114" ref-type="bibr">Wang et al., 2021</xref>). The application of nano-based delivery systems as carriers of antimalarial drugs has resolved some essential issues, such as increased therapeutic effect of conventional antimalarials with decreased resistance of <italic toggle="yes">Plasmodium</italic> sp and selective distribution of drugs (<xref rid="B1" ref-type="bibr">Abazari et al., 2020</xref>; <xref rid="B96" ref-type="bibr">Rashidzadeh et al., 2021</xref>) (<xref rid="F4" ref-type="fig">Figure 4</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Nanocarriers. <bold>(A)</bold> Nanocarriers targeting. A schematic diagram represents the active and passive targeting of NPs. In passive targeting, NPs are carried by red blood cells and in the bloodstream to all tissues. During active targeting, NPs are conjugated with affinity ligands on their surface to enhance their uptake by the target site and cells. Different targeting moieties, such as antibodies, integrins, folate, glucose, or transferrin, can interact with molecules on the target cell surface. <bold>(B)</bold> Nanocarrier uptake mechanism. In the blood, nanocarriers can be targeted to recognize only parasitized red blood cells. These reduce the chances of resistant pathogen strains and side effects for the patient since the intake is considerably low compared to traditional treatments. In addition, Plasmodium induces new permeation pathways (NPPs) that confer increased permeability to the pRBC by changing the osmotic stability and enabling nanocarriers to enter the pRBC. In other tissues, intracellular uptake of nanocarriers follows different endocytosis pathways. When nanocarriers reach the cell surface, they are taken up by endocytosis depending on their shape, charge, size, or surface. Endocytosis can occur by macropinocytosis, driven by membrane ruffling and actin protrusions. After engulfment, they fuse with lysosomal compartments to content degradation. Clathrin-mediated endocytosis is based on clathrin-coated pits on the cytosolic side of the membrane forming clathrin-coated vesicles that undergo vesicular trafficking. Caveolae-mediated endocytosis undergoes the same dynamics. However, they fuse to caveosomes, avoiding lysosomal degradation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-999300-g004.jpg"/></fig><p>Cerebral malaria is considered to be extremely severe, which is manifested by intense inflammatory conditions and severe organ damage. The drugs used for the treatment of cerebral malaria are generally administered intravenously; therefore, drug concentration and side effects are the major issues that hinder the treatment of patients with cerebral malaria. Nanostructured delivery systems can potentially treat malaria with less harm to patient (<xref rid="B49" ref-type="bibr">Golenser et al., 2020</xref>; <xref rid="B3" ref-type="bibr">Agbo et al., 2021</xref>). Different polymer-based nanoparticle structures, such as drug delivery systems, have been studied and improved in multiple studies (<xref rid="B83" ref-type="bibr">Nosrati et al., 2018</xref>; <xref rid="B94" ref-type="bibr">Ramazani et al., 2018</xref>; <xref rid="B1" ref-type="bibr">Abazari et al., 2020</xref>; <xref rid="B38" ref-type="bibr">Dias et al., 2020</xref>).</p><p>
<italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> studies used the Pfs25 sex stage gene from <italic toggle="yes">P. falciparum</italic>, harmonized by codon in <italic toggle="yes">Escherichia coli</italic> (CHrPfs25), as antigen conjugated to the gold nanoparticle (GN) in different sizes and shapes. GNs can act as a vaccine delivery vehicle because they strongly induce antibodies that block <italic toggle="yes">P. falciparum</italic> transmission. Authors found IgG from mice immunized with different GN-particles with highly potent blocking activity regardless of IgG isotype differences (<xref rid="B64" ref-type="bibr">Kumar et al., 2015</xref>).</p><p>A DNA vaccine study was carried out using magnetic vectors composed of superparamagnetic iron oxide nanoparticles (SPIONs), hyaluronic acid (HA), and polyethyleneimine (PEI) added to the DNA encoding PyMSP1 19 of <italic toggle="yes">Plasmodium yoelii</italic>. The complex induced cellular and humoral immunity against the antigen PyMSP1 19 with increased production of antibodies by an external magnetic stimulus. The immunization with the complexes induced dendritic cell maturation through the upregulation of CD86 expression in the spleen. The presence of secondary effector T cell-mediated immune responses was noted as CD4 helper T cells (Th). The complexes induced antigen-specific Th1 and Th17 cells (<xref rid="B7" ref-type="bibr">Al-Deen et al., 2017</xref>). In addition, a non-inflammatory delivery system based on polystyrene nanoparticles (PSNPs) complexed with antigen MSP4/5 (surface proteins of <italic toggle="yes">P. falciparum/P. vivax</italic> merozoites) and Freund&#8217;s adjuvants and alum was tested in a mice model. The non-inflammatory adjuvants associated with PSNPs induced a Th1 immune response acting similarly to a vaccine. The PSNPs-MSP4/5 conjugates induced immune responses by Th1 and Th2, and antibody subclasses IgG1, IgG2a, and IgG2b. The response using adjuvants was even higher. IL-4-associated with Th2 responses induced IgG1 antibodies, and IgG2 antibodies were related to Th1 responses and dependent on IFN-&#947;. Immunization protection against malaria blood-stage infection may depend on IFN-&#947; production (<xref rid="B119" ref-type="bibr">Wilson et al., 2019</xref>).</p><p>Herein, we aimed to discuss the potential application of nanotechnology in developing new antimalarial drugs and the gap between preclinical and clinical studies based on nanotechnology. <xref rid="T3" ref-type="table">Table 3</xref> presents the potential and limitations of nanotechnology.</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Main polymeric drug nano vehicles.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Nanosystems</th><th align="left" rowspan="1" colspan="1">Application potential</th><th align="left" rowspan="1" colspan="1">Application limitation</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Dendrimers</td><td align="left" rowspan="1" colspan="1">Presence of internal spaces to encapsulate drugs; external part with functional groups for conjugation and targeting of therapeutic agents; low polydispersity index; ideal for malaria treatment</td><td align="left" rowspan="1" colspan="1">High cost; possibility of loss of encapsulated substance</td><td align="left" rowspan="1" colspan="1">
<xref rid="B38" ref-type="bibr">Dias et al. (2020)</xref>, <xref rid="B127" ref-type="bibr">Hu et al. (2020)</xref>, <xref rid="B83" ref-type="bibr">Nosrati et al. (2018)</xref>, <xref rid="B130" ref-type="bibr">Sahoo et al. (2020)</xref>, <xref rid="B124" ref-type="bibr">Zhang et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanogels</td><td align="left" rowspan="1" colspan="1">Encapsulate therapeutic agents in the gel matrix by diffusion; transport and encapsulate hydrophilic and hydrophobic drugs; sustained drug release</td><td align="left" rowspan="1" colspan="1">Rapid release of therapeutic agents; therapeutic agent leakage</td><td align="left" rowspan="1" colspan="1">
<xref rid="B126" ref-type="bibr">Dawre et al. (2018)</xref>, <xref rid="B129" ref-type="bibr">Owonubi et al. (2018)</xref>, <xref rid="B96" ref-type="bibr">Rashidzadeh et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Micelles</td><td align="left" rowspan="1" colspan="1">Internalization of hydrophobic drugs with protection from degradation; control of drug release rate; decreased side effects and cytotoxicity</td><td align="left" rowspan="1" colspan="1">Micelle stability <italic toggle="yes">In vivo</italic> during blood circulation due to dilution; decreased o tempo de half-life; therapeutic agent leakage</td><td align="left" rowspan="1" colspan="1">
<xref rid="B94" ref-type="bibr">Ramazani et al. (2018)</xref>, <xref rid="B53" ref-type="bibr">Ismail et al. (2019)</xref>, <xref rid="B96" ref-type="bibr">Rashidzadeh et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Drug polymer conjugate (PDC)</td><td align="left" rowspan="1" colspan="1">Direct drug delivery to the target site; sensitive to the pH of the exposed environment for the release of therapeutic agent</td><td align="left" rowspan="1" colspan="1">May cause hemolysis</td><td align="left" rowspan="1" colspan="1">
<xref rid="B83" ref-type="bibr">Nosrati et al. (2018)</xref>, <xref rid="B96" ref-type="bibr">Rashidzadeh et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Liposomes</td><td align="left" rowspan="1" colspan="1">Ability to encapsulate hydrophobic and hydrophilic drugs; prevents degradation and promotes the delivery of a therapeutic agent to a specific site</td><td align="left" rowspan="1" colspan="1">Structural instability; drug leakage; opsonization</td><td align="left" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Fotoran et al. (2019)</xref>, <xref rid="B9" ref-type="bibr">Apolin&#225;rio et al. (2020)</xref>, <xref rid="B96" ref-type="bibr">Rashidzadeh et al. (2021)</xref>, Huang (2020)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanoparticles</td><td align="left" rowspan="1" colspan="1">Drug targeting to take the drug to the exact site of action, increasing bioavailability, concentration, and elimination of drugs</td><td align="left" rowspan="1" colspan="1">High cost</td><td align="left" rowspan="1" colspan="1">
<xref rid="B56" ref-type="bibr">Kannan et al. (2019)</xref>, <xref rid="B68" ref-type="bibr">Mart&#237; Coma-Cros et al. (2019)</xref>, <xref rid="B88" ref-type="bibr">Panzarini et al. (2018)</xref>, <xref rid="B90" ref-type="bibr">Pestehchian et al. (2020)</xref>, <xref rid="B114" ref-type="bibr">Wang et al. (2021)</xref>, <xref rid="B124" ref-type="bibr">Zhang et al. (2020)</xref>, <xref rid="B119" ref-type="bibr">Wilson et al. (2019)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Metallic and magnetic nanoparticles</td><td align="left" rowspan="1" colspan="1">Metallic and magnetic nanoparticles containing antigens of the sexual state and/or drug delivey and induction of malaria transmission-blocking immunity</td><td align="left" rowspan="1" colspan="1">Few studies on how size, shape, and surface charge affect the efficiency of immunogenicity</td><td align="left" rowspan="1" colspan="1">
<xref rid="B64" ref-type="bibr">Kumar et al. (2015)</xref>, <xref rid="B7" ref-type="bibr">Al-Deen et al. (2017)</xref>, <xref rid="B131" ref-type="bibr">Powles et al. (2020)</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>Source: Recent advances in targeting malaria with nanotechnology-based drug carriers (<xref rid="B96" ref-type="bibr">Rashidzadeh et al., 2021</xref>).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-4"><title>Recent studies on nanotechnology in malaria treatment</title><p>The number of publications on nanoparticles in treating malaria over time is increasing. For instance, a search on the National Library of Medicine USA databases found only one publication from 1990 to 2000 and 8 from 2001 to 2010. Herein, a total of 103 publications that address the study of nanoparticles in malaria treatment were analyzed. They are divided yearly into the following numbers: 2017-5 articles, 2018-9 articles, 2019-13 articles, 2020-24 articles, and 2021-21 articles (<xref rid="F5" ref-type="fig">Figure 5</xref>). In 2022, a growing number of publications that address studies related to nanoparticles in treating malaria will be noticeable. In 2022, 31 publications related to this field are available for consultation.</p><fig position="float" id="F5" orientation="portrait"><label>FIGURE 5</label><caption><p>Currently published articles on nano-formulated therapies against malaria. The illustration shows that data recorded from 2017 to 2022 were evaluated and retrieved from the National Library of Medicine USA databases (MEDLINE&#8725;PUBMED&#8212;NLM), Scientific Electronic Library Online (SciELO), and Google Scholar (Google Scholar).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-999300-g005.jpg"/></fig><p>From 2019 to 2022, multiple studies based on nanotechnology application in malaria treatment reaffirmed positive conclusions, suggesting the potential of nanosystems. Conversely, only a few ongoing clinical trials based on drug delivery for malaria treatment have been reported. In the last decade, dendrimers have caught interest for several biological applications, such as drug and gene delivery and diagnostic[S1] imaging agents (<xref rid="B10" ref-type="bibr">Araujo et al., 2018</xref>; <xref rid="B38" ref-type="bibr">Dias et al., 2020</xref>). Dendrimers are quasi-spherical, nanometer-sized, tree-like polymeric macromolecules containing many reactive functional subgroups, branches, and protected interior spaces (<xref rid="B28" ref-type="bibr">Chauhan, 2018</xref>; <xref rid="B102" ref-type="bibr">Sherje et al., 2018</xref>). The ramifications of the nanostructure generate layers, or &#8220;generations&#8221;, which characterize the size of the cavity, being the most reported in the first, second, or third generations (one, two, or three layers). These nanosystems can carry hydrophilic and hydrophobic drugs, as they have many functional groups in the periphery (<xref rid="B29" ref-type="bibr">Chis et al., 2020</xref>). Furthermore, they target drugs to specific sites and favor cellular uptake, mainly by endocytosis and passive diffusion (<xref rid="B100" ref-type="bibr">Russier et al., 2015</xref>; <xref rid="B35" ref-type="bibr">da Silva Santos et al., 2016</xref>; <xref rid="B4" ref-type="bibr">Akbarzadeh et al., 2018</xref>).</p><p>Preclinical studies using nanotechnology to treat malaria are summarized in <xref rid="T4" ref-type="table">Table 4</xref>. For instance, ultrasmall gold nanoparticles based on glucose or nanogold clusters (Glc-NCs) were developed for use in the intraerythrocytic stage of <italic toggle="yes">P. falciparum</italic> (<italic toggle="yes">in vitro</italic>) in both phases of parasitic development (asexual and sexual) without nonspecific connections or red blood cell lysis. Glc-NCs loaded with ciprofloxacin showed 50% higher antibiotic effect than that of free drug, demonstrating its therapeutic potential (<xref rid="B112" ref-type="bibr">Varela-Aramburu et al., 2020</xref>). Silver nanoparticles (AgNPs) synthesized using <italic toggle="yes">Artemisia</italic> sp leaf extract showed high antimalarial activity in <italic toggle="yes">P. falciparum</italic> cultures (<xref rid="B14" ref-type="bibr">Avitabile et al., 2020</xref>). AgNPs from <italic toggle="yes">Salvia officinalis</italic> leaf extract showed hepatoprotective and antiplasma effects, reducing parasitemia and hepatic oxidative stress markers in an experimental malaria model (<xref rid="B71" ref-type="bibr">Metwally et al., 2021</xref>). Moreover, AgNPs from <italic toggle="yes">Indigofera oblongifolia</italic> leaf extract decreased parasitemia and showed anti-inflammatory, antioxidant, and anti-apoptotic effects in mice infected by <italic toggle="yes">Plasmodium chabaudi</italic> (<xref rid="B39" ref-type="bibr">Dkhil et al., 2019</xref>).</p><table-wrap position="float" id="T4" orientation="portrait"><label>TABLE 4</label><caption><p>Summary of different drug-loaded micro- and nanoparticles reported from 2019 to 2021.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Nanoparticles Microparticles</th><th align="left" rowspan="1" colspan="1">Drug used</th><th align="left" rowspan="1" colspan="1">Types of formulation</th><th align="left" rowspan="1" colspan="1">Kind of study</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Polymeric microparticles</td><td align="left" rowspan="1" colspan="1">Primaquine</td><td align="left" rowspan="1" colspan="1">Intravenous solution</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B34" ref-type="bibr">Da Silva De Barros et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanoemulsions</td><td align="left" rowspan="1" colspan="1">Primaquine; dihydroartemisinin; thiazoline; azacarbazole<sup>&#174;</sup>
</td><td align="left" rowspan="1" colspan="1">Intravenous solution; intragastric gavage</td><td align="left" rowspan="1" colspan="1">Preclinical <italic toggle="yes">In vitro<sup>&#174;</sup>
</italic>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B111" ref-type="bibr">Umeyor et al. 2019</xref>, <xref rid="B103" ref-type="bibr">Silva and Cardoso (2020)</xref>, <xref rid="B54" ref-type="bibr">Jaromin et al. 2021</xref>, <xref rid="B120" ref-type="bibr">Wu et al. 2021</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Lipid nanoparticles/lipid carriers</td><td align="left" rowspan="1" colspan="1">Primaquine (<italic toggle="yes">in vitro/ex vivo</italic>) dihydroartemisinin; artesunate; artemether; lumefantrine; artefenomel (OZ439) (<italic toggle="yes">in vitro</italic>); curcumin</td><td align="left" rowspan="1" colspan="1">Intranasal administration; transdermal nanogel</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B101" ref-type="bibr">Salim et al. (2019)</xref>, <xref rid="B111" ref-type="bibr">Umeyor et al. (2019)</xref>, <xref rid="B48" ref-type="bibr">Ghosh and Banerjee (2020)</xref>, <xref rid="B3" ref-type="bibr">Agbo et al. (2021)</xref>, <xref rid="B51" ref-type="bibr">Guo et al. (2021)</xref>, <xref rid="B82" ref-type="bibr">Nnamani et al. (2021)</xref>, <xref rid="B120" ref-type="bibr">Wu et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Unilamerlar vesicles</td><td align="left" rowspan="1" colspan="1">Primaquine</td><td align="left" rowspan="1" colspan="1">Intravenous injection</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B6" ref-type="bibr">Al Fayes et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Liposomes/liposomes; peguilated</td><td align="left" rowspan="1" colspan="1">Primaquine; chloroquine; decoquinate ( <italic toggle="yes">in vitro</italic>)</td><td align="left" rowspan="1" colspan="1">Intravenous solution</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B40" ref-type="bibr">Duan et al. (2020)</xref>, <xref rid="B69" ref-type="bibr">Marwah et al. (2020)</xref>, <xref rid="B72" ref-type="bibr">Miatmoko et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Multilamellar nanoliposome</td><td align="left" rowspan="1" colspan="1">Chloroquine</td><td align="left" rowspan="1" colspan="1">Intraperitoneal injection</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Fotoran et al. (2019)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanodendrimer/globular nanodendrimer</td><td align="left" rowspan="1" colspan="1">Chloroquine; curcumin</td><td align="left" rowspan="1" colspan="1">1HNMR spectroscopy (<italic toggle="yes">in vitro</italic>)</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B42" ref-type="bibr">Elmi et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Dextran nanoparticle</td><td align="left" rowspan="1" colspan="1">Chloroquine diphosphate; chloroquine</td><td align="left" rowspan="1" colspan="1">Particle nanosuspension dialysis (<italic toggle="yes">in vitro</italic>)</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B58" ref-type="bibr">Kashyap et al. (2018)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Metal nanoparticles (gold, silver, ferrite, iron oxide)</td><td align="left" rowspan="1" colspan="1">Ciprofloxacin (<italic toggle="yes">in vitro</italic>); artemisinin; <italic toggle="yes">Salvia officinalis</italic>; <italic toggle="yes">Indigofera oblongifolia</italic>; artesunate</td><td align="left" rowspan="1" colspan="1">Orally inoculated; intraperitoneal injection</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Avitabile et al. (2020)</xref>, <xref rid="B39" ref-type="bibr">Dkhil et al. (2019)</xref>, <xref rid="B56" ref-type="bibr">Kannan et al. (2019)</xref>, <xref rid="B112" ref-type="bibr">Varela-Aramburu et al. (2020)</xref>, <xref rid="B124" ref-type="bibr">Zhang et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Decorated nanoparticle/nanosphere</td><td align="left" rowspan="1" colspan="1">Artemisinin</td><td align="left" rowspan="1" colspan="1">Intravenously administered</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B47" ref-type="bibr">G&#233;rard Yam&#233;ogo et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Conjugated micellar nanocomplex/nanomicelle</td><td align="left" rowspan="1" colspan="1">Artemisinin; artesunate; pyrimethamine; pluronic<sup>&#174;</sup>F127</td><td align="left" rowspan="1" colspan="1">Intravenously administered; oral solution; intragastric gavage</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B52" ref-type="bibr">He et al. (2021)</xref>, <xref rid="B53" ref-type="bibr">Ismail et al. (2019)</xref>, <xref rid="B67" ref-type="bibr">Manconi et al. (2019)</xref>, <xref rid="B68" ref-type="bibr">Mart&#237; Coma-Cros et al. (2019)</xref>, <xref rid="B90" ref-type="bibr">Pestehchian et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Conjugated nanocapsules/polysorbate</td><td align="left" rowspan="1" colspan="1">Artesunate; quinine</td><td align="left" rowspan="1" colspan="1">Intraperitoneal injection; oral solution</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B53" ref-type="bibr">Ismail et al. (2019)</xref>, <xref rid="B73" ref-type="bibr">Michels et al. (2019)</xref>, <xref rid="B76" ref-type="bibr">Moreira Souza et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Lyophilized nano suspension</td><td align="left" rowspan="1" colspan="1">Atovaquone; artesunate; artemether</td><td align="left" rowspan="1" colspan="1">Oral gavage; intradermal route; oral solution</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B59" ref-type="bibr">Kathpalia et al. (2020)</xref>, <xref rid="B113" ref-type="bibr">Volpe-Zanutto et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Pasty polymer</td><td align="left" rowspan="1" colspan="1">Artemisone</td><td align="left" rowspan="1" colspan="1">Subcutaneously injected</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B49" ref-type="bibr">Golenser et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Immunoliposomal nanovector</td><td align="left" rowspan="1" colspan="1">Atovaquone; pyronaridine</td><td align="left" rowspan="1" colspan="1">Oral delivery</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B19" ref-type="bibr">Biosca et al. (2019)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Phospholipid complex</td><td align="left" rowspan="1" colspan="1">Lumefantrine</td><td align="left" rowspan="1" colspan="1">Subcutaneous or intramuscular injection</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B61" ref-type="bibr">Kaur et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanogel</td><td align="left" rowspan="1" colspan="1">Artemether</td><td align="left" rowspan="1" colspan="1">Nanog&#233;is ART transd&#233;rmicos</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B82" ref-type="bibr">Nnamani et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Zein nanoparticles</td><td align="left" rowspan="1" colspan="1">Artemether</td><td align="left" rowspan="1" colspan="1">Intravenously administered</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B20" ref-type="bibr">Boateng-Marfo et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Flash nanoprecipitation</td><td align="left" rowspan="1" colspan="1">Lumefantrine; artefenomel (OZ439)</td><td align="left" rowspan="1" colspan="1">Oral delivery</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B98" ref-type="bibr">Ristroph et al. (2019)</xref>, <xref rid="B114" ref-type="bibr">Wang et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutral nanoparticle</td><td align="left" rowspan="1" colspan="1">Curcumin</td><td align="left" rowspan="1" colspan="1">Oral delivery</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B18" ref-type="bibr">Biosca et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nutrissomes</td><td align="left" rowspan="1" colspan="1">Curcumin</td><td align="left" rowspan="1" colspan="1">Oral solution</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B67" ref-type="bibr">Manconi et al. (2019)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gold nanoparticle</td><td align="left" rowspan="1" colspan="1">Antigens delivery</td><td align="left" rowspan="1" colspan="1">Subcutaneous or intramuscular injection</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B64" ref-type="bibr">Kumar et al. 2015</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Superparamagnetic nanoparticles</td><td align="left" rowspan="1" colspan="1">Magnetic nanovector</td><td align="left" rowspan="1" colspan="1">Subcutaneous or intramuscular injection</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B128" ref-type="bibr">Nawwab al-deen et al. (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Polystyrene nanoparticles</td><td align="left" rowspan="1" colspan="1">Non-inflammation-inducing polystyrene nanoparticle delivery system</td><td align="left" rowspan="1" colspan="1">Subcutaneous or intramuscular injection</td><td align="left" rowspan="1" colspan="1">Preclinical</td><td align="left" rowspan="1" colspan="1">
<xref rid="B119" ref-type="bibr">Wilson et al. (2019)</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>Source: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/</ext-link>.</p></fn></table-wrap-foot></table-wrap><p>Hollow nanoparticles of mesoporous ferrite (HMFNs) with ferromagnetic properties were prepared using artemisinin and targeted to hemozoin produced by <italic toggle="yes">P. falciparum</italic> in infected erythrocytes. It acted as a targeted delivery system, increasing the local concentration of ART through its association with heparin, suggesting its potential in antimalarial therapy (<xref rid="B114" ref-type="bibr">Wang et al., 2021</xref>). Surface-loaded nanoparticles containing ART in two types of formulations (nanospheres and nanocapsules) had longer elimination half-life than that of an ART solution in ethanol, suggesting their potential as intravenous antimalarial agents (<xref rid="B47" ref-type="bibr">G&#233;rard Yam&#233;ogo et al., 2020</xref>). Furthermore, a stable ART-based injectable nanocomplex, composed of dimorphic artesunate-choline (dACC) micelles coated with hyaluronic acid (HA), demonstrated safety and antimalarial activity in <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments compared to those of free artemisinin/artesunate, suggesting it as a promising injectable alternative to the traditional artesunate (ATS) used in malaria treatment (<xref rid="B52" ref-type="bibr">He et al., 2021</xref>).</p><p>
<italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> studies have shown that lipid nanoemulsions with modified surface are ideal carriers of dihydroartemisinin (<xref rid="B111" ref-type="bibr">Umeyor et al., 2019</xref>). Ester-linked dihydroartemisinin trimer (DHA 3) prepared as self-assembled nanoparticles (DHA 3 NPs) demonstrated superior antimalarial effects compared to that of control in a murine experimental model, with improved cure rate and survival time and reduced recurrence rate in experimental animals (<xref rid="B51" ref-type="bibr">Guo et al., 2021</xref>). ATS fortified with iron oxide-coated nanoparticles showed increased cytotoxicity and selective damage to <italic toggle="yes">P. falciparum</italic> in a murine experimental model, suggesting a potent antimalarial agent against artemisinin-resistant malaria (<xref rid="B56" ref-type="bibr">Kannan et al., 2019</xref>). Nanostructured lipid carriers (NLCs) loaded with ATS for intranasal administration (ATS-NLCs) showed great potential as an alternative to parenteral administration in hard-to-reach regions, simplifying the treatment of severe and cerebral malaria in adults and children (<xref rid="B3" ref-type="bibr">Agbo et al., 2021</xref>). The nanocapsules based on artesunate-heparin conjugate (ATS-HEP-NCPs) were used as drug delivery vehicle for intracellular release; <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments showed increased stability and improved pharmacokinetic properties (<xref rid="B53" ref-type="bibr">Ismail et al., 2019</xref>). In a murine experimental model, the triple combination containing atovaquone in a lyophilized suspension of proguanil-artesunate demonstrated prophylactic efficacy.</p><p>In addition, the use of double (atovaquone/proguanil) and triple (atovaquone/proguanil/artesunate) combination formulations resulted in a complete cure (<xref rid="B59" ref-type="bibr">Kathpalia et al., 2020</xref>). The injectable pasty polymer, formulated for controlled release of artemisinin, reduced parasitemia and severe symptoms in cerebral malaria and increased survival of animals, with an increase in the half-life of the drug compared to that of free drug in an experimental murine model (<xref rid="B49" ref-type="bibr">Golenser et al., 2020</xref>). The nanovector immunoliposomal encapsulating the antimalarials pyronaridine and atovaquone, which block the development of gametocytes through targeting glycophorin <italic toggle="yes">in vitro</italic>, presented significantly higher efficacy than that of the free forms (<xref rid="B19" ref-type="bibr">Biosca et al., 2019</xref>).</p><p>The improved solubility of lumefantrine (LUM) in an aqueous medium by using lumefantrine phospholipid complex (LMF-PC) enhanced antimalarial activity in a murine model (<xref rid="B61" ref-type="bibr">Kaur et al., 2021</xref>). The matrices of microneedle (MN) containing ART (MN-ART) and LUM (MN-LUM) in nanosuspensions, applied as intradermal devices, showed increased solubility of drugs and potential as an alternative treatment for malaria in endemic regions with scarce resources (<xref rid="B113" ref-type="bibr">Volpe-Zanutto et al., 2021</xref>). Transdermal artemether nanogel (TMT) as NLCs have demonstrated good antimalarial properties in <italic toggle="yes">in vitro</italic> and <italic toggle="yes">ex vivo</italic> skin permeation experiments. They offered 100% cure and negligible side effects when two adhesives were applied per week at a lower dose than that of free TMT (<xref rid="B82" ref-type="bibr">Nnamani et al., 2021</xref>). Zein nanoparticles loaded with TMT showed good encapsulation efficiency, reduced hemolysis, and prolonged therapeutic effect compared to that of free TMT (<xref rid="B20" ref-type="bibr">Boateng-Marfo et al., 2021</xref>). Caprol-based NLCs were prepared to improve the bioavailability of artemether/lumefantrine antimalarials; they showed improved oral bioavailability, antimalarial activity, and potential compared to those of free antimalarials (<xref rid="B5" ref-type="bibr">Akpa et al., 2020</xref>). In addition, nanocapsules (NC-ATM) showed decreased neurotoxic and cardiotoxic effects in mice infected with <italic toggle="yes">Plasmodium berghei</italic>, a safe alternative to TMT for the treatment of malaria (<xref rid="B76" ref-type="bibr">Moreira Souza et al., 2020</xref>). Flash nanoprecipitation (FNP) is a technique that enables the production of nanoparticles from laboratory-scale to industrial pilot-scale. Lumefantrine was processed by FNP to obtain 200&#160;nm nanoparticles with increased bioavailability and dissolution kinetics suitable for industrial-scale production (<xref rid="B98" ref-type="bibr">Ristroph et al., 2019</xref>). The technique (FNP) was employed for formulation of the substance OZ439 (artefenomel), which is active against drug-resistant malaria, and the formulation showed potential as a single-dose cure. Powder formulations using spray dryer is appropriate for industrial-scale production. <italic toggle="yes">In vitro</italic> tests have shown that the formulation of the antimalarial OZ439 in a single-dose oral form had good stability against humidity and temperature (<xref rid="B98" ref-type="bibr">Ristroph et al., 2019</xref>). The oral bioavailability of OZ439 and the adjustment of interactions by selecting alternative systems such as milk-like lipid nanoparticles or powder systems can provide different possibilities for enhanced solubilization and absorption for this drug (<xref rid="B101" ref-type="bibr">Salim et al., 2019</xref>).</p><p>Neutral zwitterionic amphiphiles forming nanoparticles (PBMA-MESBMA) using curcumin and targeted to infected erythrocytes showed effective and faster antimalarial activity than that of free curcumin in an animal model (<xref rid="B18" ref-type="bibr">Biosca et al., 2021</xref>). Nutrisomes (phospholipid vesicles + Nutriose<sup>&#174;</sup> FM06) were modified to obtain new systems with increased efficacy of curcumin as an antimalarial agent after oral administration. Eudragit<sup>&#174;</sup> L100 (EUD) was added to these vesicles to improve their <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> performance, which showed an increased ability to neutralize oxidative stress in intestinal cells and increased survival of infected mice compared to controls treated with free curcumin (<xref rid="B67" ref-type="bibr">Manconi et al., 2019</xref>). The nanocapsules (NCP80) and nanospheres (NSP80) of polysorbate 80 and nanocapsules (NCEUD) and nanospheres (NSEUD) of Eudragit RS 100 containing quinine were evaluated for their effects on the surface characteristics and antimalarial efficacy <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. Cationic and anionic nanocapsules have been developed to deliver quinine to erythrocytes using Eudragit RS 100. An improvement in antiplasmodial efficacy was observed along with altered characteristics of the cationic nanocapsules with quinine such as protection against light and improvement of quinine partition coefficient <italic toggle="yes">in vitro</italic>. Improvement in biodistribution of quinine by NCEUD and increase in the half-life of elimination of quinine <italic toggle="yes">in vivo</italic> suggest it as a potential alternative for the treatment of malaria (<xref rid="B73" ref-type="bibr">Michels et al., 2019</xref>). The nanoformulation of curcumin in combination with the compound benzothiophene 6 (3-bromine-N-(4-fluorobenzyl)-benzo[b]thiophene-2-carboxamide) showed sustained release of curcumin, increased stability and solubility in aqueous medium, and antimalarial activity in in <italic toggle="yes">vivo</italic> and <italic toggle="yes">in vitro</italic> experiments (<xref rid="B48" ref-type="bibr">Ghosh and Banerjee, 2020</xref>).</p><p>The nanoemulsion delivery system of azacarbazoles, derived from carbazole (9 H-carbazole) with a concentrated form of ethyl esters of polyunsaturated fatty acids n-3 and n-6, provided evidence of increased antiplasmodial activities <italic toggle="yes">in vitro,</italic> without cytotoxic effects against mammalian cells, showing rapid absorption after intragastric administration (<xref rid="B54" ref-type="bibr">Jaromin et al., 2021</xref>). In addition, thiazoline nanoemulsion (10-(4,5-dihydrothiazol-2-yl)thio)decan-1-ol), a synthetic compound similar to 3-alkylidene marine alkaloid being reported as an antimalarial substance, reduced <italic toggle="yes">in vivo</italic> parasitemia and increased antimalarial activity <italic toggle="yes">in vitro</italic> (<xref rid="B103" ref-type="bibr">Silva and cordoso., 2020</xref>). The 407 poloxamer nanomicelles loaded with pyrimethamine showed potent antimalarial activity and lower liver damage in a murine experiment than that of the free compound, indicating potential for adaptation as an antimalarial formulation (<xref rid="B90" ref-type="bibr">Pestehchian et al., 2020</xref>). <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> experiments have shown that hybrid dendritic-linear-dendritic block copolymer mycelial transporters based on Pluronic<sup>&#174;</sup> F127 (HDLDBC-bGMPA) are promising for the development of future antimalarial drugs aimed at penetrating erythrocytes (&lt;30&#160;nm) infected by <italic toggle="yes">Plasmodium</italic> sp (<xref rid="B68" ref-type="bibr">Mart&#237; Coma-Cros et al., 2019</xref>). <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> experiments of artelinic acid (AD) derivatives formulated as liposomes (ADLs) showed superior antimalarial efficacy compared with that of the control groups. Pharmacokinetic results of ADLs demonstrated the slowest elimination and highest total concentration in plasma, showing potential for the treatment of malaria (<xref rid="B40" ref-type="bibr">Duan et al., 2020</xref>).</p><p>Furthermore, primaquine polymeric microparticles (PPM) in <italic toggle="yes">in vivo</italic> experiments using a murine model showed partial efficacy and protection against parasite development compared with that of free primaquine, suggesting the potential of this drug delivery system for the treatment of malaria (<xref rid="B34" ref-type="bibr">da Silva de Barros et al., 2021</xref>). Three drug carriers based on lipid formulations loaded with primaquine, solid lipid nanoparticles, nanoemulsions and nanostructured lipid carriers were developed and evaluated; all lipid formulations could successfully protect erythrocytes from cell lysis caused by free primaquine (<xref rid="B120" ref-type="bibr">Wu et al., 2021</xref>). Phospholipid-free unilamellar vesicles (PFSUVs) composed of Tween 80 and cholesterol were evaluated in experimental models <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. They effectively delivered primaquine to the liver, selectively targeted hepatocytes, and reduced erythrocyte uptake compared to that of free primaquine, leading to reduced erythrocyte toxicity (<xref rid="B6" ref-type="bibr">Al Fayes et al., 2021</xref>). <italic toggle="yes">In vivo</italic> experiments with PEGylated liposomes containing primaquine and chloroquine for the treatment of malaria in the hepatic stage demonstrated that liposomal membrane fluidity was greatly affected by the double burden of primaquine and chloroquine drugs, and additional studies related to stabilization of these liposomes are needed (<xref rid="B72" ref-type="bibr">Miatmoko et al., 2021</xref>). Decoquinate (DQN) is a molecule that can potentially function as a substitute for active primaquine against malaria in the hepatic stage was directed to hepatocytes infected by the parasite using a liposomal transporter system <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. The study concluded that glycyrrhizic acid receptors participated in the targeted delivery of DQN liposomes to the hepatocytes (<xref rid="B69" ref-type="bibr">Marwah et al., 2020</xref>). Multilamellar nanoliposomes stabilized by hydrogen bonds containing chloroquine targeted to infected erythrocytes showed antiparasitic effect superior to that of free chloroquine in <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies, being permissive for smaller and larger molecules (<xref rid="B44" ref-type="bibr">Fotoran et al., 2019</xref>). The loading of chloroquine in G2 nanodendrimers showed antiplasmodial activity and decreased toxicity of structured nano chloroquine compared to that of free chloroquine, indicating that this compound is an effective antiplasmodic agent <italic toggle="yes">in vivo</italic> in a murine model (<xref rid="B42" ref-type="bibr">Elmi et al., 2021</xref>). 1H NMR spectroscopy was used to study the effect of anionic linear globular dimerized nanocomplexes based on curcumin loaded with chloroquine G2 and antiplasmodial effect against <italic toggle="yes">P. falciparum in vitro</italic> (<xref rid="B42" ref-type="bibr">Elmi et al., 2021</xref>). In addition, dextran NPs loaded with chloroquine diphosphate (CHQ-DEX-NPs) were developed to overcome resistance of <italic toggle="yes">P. falciparum</italic> to chloroquine <italic toggle="yes">in vitro</italic>. CHQ-DEX-NPs could trigger the parasite&#8217;s apoptotic pathway by accumulating in food vacuoles and were found safe for parenteral administration (<xref rid="B58" ref-type="bibr">Kashyap et al., 2018</xref>). The biocompatible and biodegradable nanoparticles of chitosan-tripolyphosphate-chloroquine triggered elimination of multidrug-resistant parasites through redox action, modulating pro- and anti-inflammatory responses, suggesting a new approach to treat multidrug-resistant malaria. The CS-TPP CQ nanoparticles killed the parasite and diminished the production of the pro-inflammatory cytokines TNF-&#945; and IFN-&#947;, and increased the anti-inflammatory cytokines IL-10 and TGF-&#946; (<xref rid="B36" ref-type="bibr">Das et al., 2021</xref>). The incorporation of proteins or peptides of interest can occur both during the preparation of the NP (e.g., antigens), and through their complexation/conjugation on the nanocarrier surface (e.g., plasmids or antibodies). For example, <xref rid="B133" ref-type="bibr">Cherif et al. (2011)</xref> developed polymeric NPs formed by pDNA complexed with PEI (cationic polymer) and PLA (biocompatible polymer), which were tested <italic toggle="yes">in vivo</italic> against <italic toggle="yes">P. yoelii</italic> in different administration routes (IV, SC, and IP) in mice. They observed an increase in the immune response regarding the levels of IgG, T cells (CD4<sup>+</sup> and CD8<sup>+</sup>), IFN-&#947; and IL-12. Another study carried out by <xref rid="B132" ref-type="bibr">Collins et al. (2017)</xref> developed NPs conjugated to the surface antigen of the circumsporozoite protein CSP-hepatitis B, acting in the pre-erythrocyte stage of infection by <italic toggle="yes">P. falciparum</italic>. Moderate levels of protection were induced through the immune response mediated by CSP-specific antibodies. In addition, this vaccine was immunogenic (cellular and humoral immune response) at low doses. Also, when administered with Abisco-100 and Matrix-M adjuvants, it induced protection against transgenic sporozoites (<xref rid="B132" ref-type="bibr">Collins, 2017</xref>).</p><p>Articles have discussed the multi-component vaccination to challenge both humoral and cellular immunity and adjuvants as the best strategy to reach all stages of malaria.</p><p>The association of polymeric and lipid NPs is also described, as reported by <xref rid="B64" ref-type="bibr">Kumar et al. (2015)</xref>. Nanoemulsion containing squalene, chitosan/PLGA NPs and CHrPfs25 were developed and evaluated against <italic toggle="yes">P. falciparum.</italic> Results regarding the functional immunogenicity generated by CHrPfs25 are promising. Authors found IgG from mice immunized with different GN-particles with highly potent blocking activity regardless of IgG isotype differences. Most studies in this article suggest nanoformulations as drug delivery systems, indicating their potential for the treatment of malaria (<xref rid="T4" ref-type="table">Table 4</xref>).</p></sec><sec id="s3-5"><title>Limitations of nanotechnology in malaria treatment</title><p>Nanotechnology has enormous potential for the development of new drugs against malaria, although there are limitations. Despite significant advantages of nano-pharmaceutical release systems, factors such as high preparation cost, interaction with biological components, difficulty in production scale up depending on the development method, failure to define the appropriate route of administration, and failure in therapeutic reproducibility demotivated researchers to lead preclinical research for clinical application (<xref rid="B81" ref-type="bibr">Neves Borgheti-Cardoso et al., 2020</xref>; <xref rid="B96" ref-type="bibr">Rashidzadeh et al., 2021</xref>).</p><p>The cost of producing nanosystems is a primary concern for their use in treating diseases such as malaria. The large-scale production of nano drugs to provide access in malaria predominant regions is difficult due to financial, logistical, and political issues, among other limiting factors (<xref rid="B43" ref-type="bibr">Feng et al., 2019</xref>; <xref rid="B98" ref-type="bibr">Ristroph et al., 2019</xref>). In addition, majority of malaria-affected population is concentrated in developing countries, which have low resources invested in health and medical care. This panorama of resource scarcity failed to foster industry interest in the development of new antimalarial medicines on a large scale because of low financial returns (<xref rid="B98" ref-type="bibr">Ristroph et al., 2019</xref>; <xref rid="B113" ref-type="bibr">Volpe-Zanutto et al., 2021</xref>).</p><p>Despite considerable volume of studies based on nanotechnology application for the treatment of malaria, it is possible to perceive a difference between the number of preclinical and clinical studies, which are lower. Preclinical studies that employ nanoparticles in other diseases, such as cancer, tumors, and Alzheimer&#8217;s disease, present more signifying results and often involve theranostic nanomedicine (<xref rid="B46" ref-type="bibr">Gandhi et al., 2020</xref>; <xref rid="B2" ref-type="bibr">Abdolmaleki et al., 2021</xref>). High cost of preparation, drug administration routes, bioaccumulation, toxicity, and interaction with biological components are some critical issues to be resolved to contemplate the success of new nanotechnological strategies for the treatment of malaria (<xref rid="B9" ref-type="bibr">Apolin&#225;rio et al., 2020</xref>; <xref rid="B96" ref-type="bibr">Rashidzadeh et al., 2021</xref>).</p><p>To overcome the clinical failures of antimalarial therapy, developing new medicines is urgent and necessary. However, developing a new drug is expensive, complex, and time-consuming. In this case, strategies that increase the therapeutic efficacy of current conventional antimalarial drugs and reduce their toxicity are promising alternatives. For that, nanotechnology can be considered an approach to solving these inherent limitations, such as the low water solubility, biodegradability, bioavailability, and parasite resistance (<xref rid="B55" ref-type="bibr">Jawahar et al., 2019</xref>; <xref rid="B92" ref-type="bibr">Puttappa et al., 2019</xref>; <xref rid="B95" ref-type="bibr">Rashidzadeh et al., 2019</xref>; <xref rid="B1" ref-type="bibr">Abazari et al., 2020</xref>; <xref rid="B15" ref-type="bibr">Bagheri et al., 2020</xref>). Several organic, inorganic, and hybrid nanometric systems were discussed in this review and offer many alternatives as drug delivery systems for antimalarial drugs (<xref rid="T3" ref-type="table">Table 3</xref>). Therefore, these efforts must be continued to accelerate the clinical application of these systems to treat malaria.</p><p>Some companies have explored the potential of dendrimers. For instance, Starpharma developed the DEP<sup>&#174;</sup> platform for drug delivery applied to antitumor drugs. Or diagnostic kits component as 3DNA<sup>&#174;</sup> from Gemisphere, or transfection agents such as Polyfect<sup>&#174;</sup> and Superfect<sup>&#174;</sup> from Qiagen (<xref rid="B38" ref-type="bibr">Dias et al., 2020</xref>). In addition, according to information from the American repository <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrial.gov" ext-link-type="uri">ClinicalTrial.gov</ext-link>, some clinical trials evaluate drugs associated with dendrimers for treating cancer, bacterial infection, or COVID-19 (<xref rid="B25" ref-type="bibr">Caminade, 2022</xref>). However, up to date, there are no dendrimer-based medicines to treat malaria, either under clinical evaluation or commercialization.</p></sec></sec><sec sec-type="conclusion" id="s4"><title>Conclusion</title><p>Malaria is a disease affecting millions of people worldwide. Despite the current treatments, resistance to antimalarial drugs has increased. Advances in nanotechnology for the development of new drug delivery systems are promising and being increasingly studied in preclinical tests, with significant and instigating results. However, no nano-formulated antimalarial drug is currently available for clinical use.</p><p>New approaches to malaria treatment are urgently needed owing to the complexity of the biological cycle of the parasite, spread of the disease in conditions where sanitary and social conditions are precarious, and reports of resistance of the parasite to conventional therapies. The interaction between academic research, pharmaceutical industry, and political leaders is the most promising path for the development of new drugs and nanostructured drug delivery systems.</p></sec></body><back><ack><p>We also acknowledge financial support by the European Community&#8217;s Seventh Framework Programme (FP7-2007-2013) under grant agreement (HEALTH-F4-2011-282095) (TARKINAID).</p></ack><sec id="s5"><title>Author contributions</title><p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p></sec><sec id="s6"><title>Funding</title><p>This work was supported by grants from Universidade Federal Fluminense (PROPPI/UFF), Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior (CAPES) Grant [001], Programa de Biotecnologia da Universidade Federal Fluminense (UFF), Programa de P&#243;s Gradua&#231;&#227;o em Biologia Molecular Celular (UNIRIO), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Funda&#231;&#227;o Carlos Chagas Filho de Amparo &#224; Pesquisa do Estado do Rio de Janeiro (FAPERJ) Grants (E-26/010.000983/2019, E-26/203.290/2017, and E-26/2010.592/2019, E-26/201.448/2021), Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico (CNPq), and Instituto Oswaldo Cruz, FIOCRUZ.</p></sec><sec sec-type="COI-statement" id="s7"><title>Conflict of interest</title><p>Author FN was employed by Empresa Brasileira de Pesquisa Agropecu&#225;ria, EMBRAPA.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s8"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abazari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghaffari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rashidzadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Momeni Badeleh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maleki</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Current status and future outlook of nano-based systems for burn wound management</article-title>. <source>J. Biomed. Mat. Res. B Appl. Biomater.</source><volume>108</volume>, <fpage>1934</fpage>&#8211;<lpage>1952</lpage>. <pub-id pub-id-type="doi">10.1002/jbm.b.34535</pub-id><pub-id pub-id-type="pmid">31886606</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdolmaleki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Asadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gurushankar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shayan</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Sarvestani</surname><given-names>F. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Importance of nano medicine and new drug therapies for cancer</article-title>. <source>Adv. Pharm. Bull.</source><volume>11</volume>, <fpage>450</fpage>&#8211;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.34172/apb.2021.052</pub-id><pub-id pub-id-type="pmid">34513619</pub-id><pub-id pub-id-type="pmcid">PMC8421622</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agbo</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Ugwuanyi</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Ugwuoke</surname><given-names>W. I.</given-names></name><name name-style="western"><surname>Mcconville</surname><given-names>C.</given-names></name><name name-style="western"><surname>Attama</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Ofokansi</surname><given-names>K. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Intranasal artesunate-loaded nanostructured lipid carriers: A convenient alternative to parenteral formulations for the treatment of severe and cerebral malaria</article-title>. <source>J. Control. Release</source><volume>334</volume>, <fpage>224</fpage>&#8211;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.04.020</pub-id><pub-id pub-id-type="pmid">33894303</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbarzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khalilov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mostafavi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Annabi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Abasi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kafshdooz</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Role of dendrimers in advanced drug delivery and biomedical applications: A review</article-title>. <source>Exp. Oncol.</source><volume>40</volume>, <fpage>178</fpage>&#8211;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.31768/2312-8852.2018.40(3):178-183</pub-id><pub-id pub-id-type="pmid">30285011</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akpa</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Ugwuoke</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Attama</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Nnenna Ugwu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nneoma Ezeibe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Momoh</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration</article-title>. <source>Afr. Health Sci.</source><volume>20</volume> (<issue>4</issue>), <fpage>1679</fpage>&#8211;<lpage>1697</lpage>. <pub-id pub-id-type="doi">10.4314/ahs.v20i4.20</pub-id><pub-id pub-id-type="pmid">34394228</pub-id><pub-id pub-id-type="pmcid">PMC8351851</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Fayes</surname><given-names>N.</given-names></name><name name-style="western"><surname>B&#246;ttger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rouhollahi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Witzigmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S. D.</given-names></name></person-group> (<year>2021</year>). <article-title>Improved liver delivery of primaquine by phospholipid-free small unilamellar vesicles with reduced hemolytic ToxicityNo title</article-title>. <source>Mol. Pharm.</source><volume>19</volume> (<issue>6</issue>), <fpage>1778</fpage>&#8211;<lpage>1785</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00520</pub-id><pub-id pub-id-type="pmid">34546758</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Deen</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Selomulya</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>).<article-title>Magnetic nanovectors for the development of DNA blood-stage malaria vaccines</article-title>, <source>Nanomaterials (Basel)</source>, <volume>7</volume>. , <fpage>E30</fpage>. <pub-id pub-id-type="doi">10.3390/nano7020030</pub-id><pub-id pub-id-type="pmid">28336871</pub-id><pub-id pub-id-type="pmcid">PMC5333015</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alven</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aderibigbe</surname><given-names>B. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Nanoparticles formulations of artemisinin and derivatives as potential therapeutics for the treatment of cancer, leishmaniasis and Malaria</article-title>. <source>Pharmaceutics</source><volume>12</volume> (<issue>8</issue>), <fpage>748</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12080748</pub-id><pub-id pub-id-type="pmcid">PMC7466127</pub-id><pub-id pub-id-type="pmid">32784933</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apolin&#225;rio</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Salata</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. F. R.</given-names></name><name name-style="western"><surname>Fukumori</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>L. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Opening the pandora's box of nanomedicine: There is needed plenty of room at the bottom</article-title>. <source>Quimica Nova</source><volume>43</volume>, <fpage>212</fpage>&#8211;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.21577/0100-4042.20170481</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araujo</surname><given-names>R. V.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>S. D. S.</given-names></name><name name-style="western"><surname>Igne Ferreira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giarolla</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>New advances in general biomedical applications of PAMAM dendrimers</article-title>. <source>Molecules</source><volume>23</volume>, <fpage>E2849</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23112849</pub-id><pub-id pub-id-type="pmid">30400134</pub-id><pub-id pub-id-type="pmcid">PMC6278347</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashley</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Phyo</surname><given-names>A. P.</given-names></name></person-group> (<year>2018</year>). <article-title>Drugs in development for malaria</article-title>. <source>Drugs</source><volume>78</volume>, <fpage>861</fpage>&#8211;<lpage>879</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-018-0911-9</pub-id><pub-id pub-id-type="pmid">29802605</pub-id><pub-id pub-id-type="pmcid">PMC6013505</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashley</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Pyae Phyo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Woodrow</surname><given-names>C. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Malaria</article-title>. <source>Lancet</source><volume>391</volume>, <fpage>1608</fpage>&#8211;<lpage>1621</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)30324-6</pub-id><pub-id pub-id-type="pmid">29631781</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Devine</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>M&#246;hrle</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Laleu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Charman</surname><given-names>S. A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The development process for discovery and clinical advancement of modern antimalarials</article-title>. <source>J. Med. Chem.</source><volume>62</volume>, <fpage>10526</fpage>&#8211;<lpage>10562</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00761</pub-id><pub-id pub-id-type="pmid">31385706</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avitabile</surname><given-names>E.</given-names></name><name name-style="western"><surname>Senes</surname><given-names>N.</given-names></name><name name-style="western"><surname>D&#8217;avino</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tsamesidis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pinna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medici</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The potential antimalarial efficacy of hemocompatible silver nanoparticles from Artemisia species against P. falciparum parasite</article-title>. <source>PLoS ONE</source><volume>15</volume>, <fpage>02385322</fpage>&#8211;<lpage>e238617</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0238532</pub-id><pub-id pub-id-type="pmcid">PMC7462267</pub-id><pub-id pub-id-type="pmid">32870934</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagheri</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Golenser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Greiner</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Controlled and manageable release of antimalarial Artemisone by encapsulation in biodegradable carriers</article-title>. <source>Eur. Polym. J.</source><volume>129</volume>, <fpage>109625</fpage>. <pub-id pub-id-type="doi">10.1016/j.eurpolymj.2020.109625</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baruah</surname><given-names>U. K.</given-names></name><name name-style="western"><surname>Gowthamarajan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vanka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karri</surname><given-names>V. V. S. R.</given-names></name><name name-style="western"><surname>Selvaraj</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jojo</surname><given-names>G. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Malaria treatment using novel nano-based drug delivery systems</article-title>. <source>J. Drug Target.</source><volume>25</volume>, <fpage>567</fpage>&#8211;<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1080/1061186X.2017.1291645</pub-id><pub-id pub-id-type="pmid">28166440</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belete</surname><given-names>T. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Recent progress in the development of new antimalarial drugs with novel targets</article-title>. <source>Drug Des. devel. Ther.</source><volume>14</volume>, <fpage>3875</fpage>&#8211;<lpage>3889</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S265602</pub-id><pub-id pub-id-type="pmcid">PMC7519860</pub-id><pub-id pub-id-type="pmid">33061294</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biosca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cabanach</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abdulkarim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gumbleton</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#243;mez-Canela</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ram&#237;rez</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Zwitterionic self-assembled nanoparticles as carriers for Plasmodium targeting in malaria oral treatment</article-title>. <source>J. Control. Release</source><volume>331</volume>, <fpage>364</fpage>&#8211;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.01.028</pub-id><pub-id pub-id-type="pmid">33497747</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biosca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dirscherl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moles</surname><given-names>E.</given-names></name><name name-style="western"><surname>Imperial</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fern&#224;ndez-Busquets</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>). <article-title>An immunopegliposome for targeted antimalarial combination therapy at the nanoscale</article-title>. <source>Pharmaceutics</source><volume>11</volume>, <fpage>3411</fpage>&#8211;<lpage>E419</lpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics11070341</pub-id><pub-id pub-id-type="pmcid">PMC6680488</pub-id><pub-id pub-id-type="pmid">31315185</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boateng-Marfo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kiong Ng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.-S.</given-names></name></person-group> (<year>2021</year>). <article-title>Artemether-loaded zein nanoparticles: An innovative intravenous dosage form for the management of severe malaria</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume> (<issue>3</issue>), <fpage>1141</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22031</pub-id><pub-id pub-id-type="pmid">33498911</pub-id><pub-id pub-id-type="pmcid">PMC7865387</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brazier</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Avril</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bernabeu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Dzikowski</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Pathogenicity determinants of the human malaria parasite plasmodium falciparum have ancient origins</article-title>. <source>ASM Journals</source><volume>2</volume>. <pub-id pub-id-type="doi">10.1128/mSphere.00348-16</pub-id><pub-id pub-id-type="pmcid">PMC5227068</pub-id><pub-id pub-id-type="pmid">28101534</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bree</surname><given-names>D.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>Drug resistance in plasmodium</article-title>. <source>Nat. Rev. Microbiol.</source><volume>176</volume>, <fpage>139</fpage>&#8211;<lpage>148</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro.2017.161</pub-id><pub-id pub-id-type="pmcid">PMC6371404</pub-id><pub-id pub-id-type="pmid">29355852</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito-Sousa</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Avalos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fontecha</surname><given-names>G.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Val</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Clinical spectrum of primaquine-induced hemolysis in glucose-6-phosphate dehydrogenase deficiency: A 9-year hospitalization-based study from the Brazilian amazon</article-title>. <source>Clin. Infect. Dis.</source><volume>69</volume>, <fpage>1440</fpage>&#8211;<lpage>1442</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciz122</pub-id><pub-id pub-id-type="pmid">30753364</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calder&#243;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fornaguera</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zadoina</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dols-Perez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Solans</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Design of parenteral MNP-loaded PLGA nanoparticles by a low-energy emulsification approach as theragnostic platforms for intravenous or intratumoral administration</article-title>. <source>Colloids Surf. B Biointerfaces</source><volume>160</volume>, <fpage>535</fpage>&#8211;<lpage>542</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2017.09.060</pub-id><pub-id pub-id-type="pmid">29024918</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caminade</surname><given-names>A. M.</given-names></name></person-group> (<year>2022</year>). <article-title>Dendrimers, an emerging opportunity in personalized medicine?</article-title><source>J. Pers. Med.</source><volume>12</volume>, <fpage>1334</fpage>. <pub-id pub-id-type="doi">10.3390/jpm12081334</pub-id><pub-id pub-id-type="pmid">36013283</pub-id><pub-id pub-id-type="pmcid">PMC9409959</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capela</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>F.</given-names></name></person-group> (<year>2019</year>). <article-title>An overview of drug resistance in protozoal diseases</article-title>. <source>Int. J. Mol. Sci.</source><volume>20</volume>, <fpage>E5748</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20225748</pub-id><pub-id pub-id-type="pmid">31731801</pub-id><pub-id pub-id-type="pmcid">PMC6888673</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charlie-Silva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fraceto</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>De Melo</surname><given-names>N. F. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Progress in nano-drug delivery of artemisinin and its derivatives: Towards to use in immunomodulatory approaches</article-title>. <source>Artif. Cells Nanomed. Biotechnol.</source><volume>46</volume>, <fpage>S611</fpage>&#8211;<lpage>S620</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2018.1505739</pub-id><pub-id pub-id-type="pmid">30444132</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>A. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Dendrimers for drug delivery</article-title>. <source>Molecules</source><volume>23</volume>, <fpage>E938</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23040938</pub-id><pub-id pub-id-type="pmid">29670005</pub-id><pub-id pub-id-type="pmcid">PMC6017392</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherif</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Shuaibu</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Kurosaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Helegbe</surname><given-names>G. K.</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yanagi</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration</article-title>. <source>Vaccine</source><volume>29</volume> (<issue>48</issue>), <fpage>9038</fpage>&#8211;<lpage>9050</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.031</pub-id><pub-id pub-id-type="pmid">21939717</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chis</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Dobrea</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morgovan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arseniu</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Rus</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Butuca</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Applications and limitations of dendrimers in biomedicine</article-title>. <source>Molecules</source><volume>25</volume>, <fpage>E3982</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25173982</pub-id><pub-id pub-id-type="pmid">32882920</pub-id><pub-id pub-id-type="pmcid">PMC7504821</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coban</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M. S. J.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Tissue-specific immunopathology during malaria infection</article-title>. <source>Nat. Rev. Immunol.</source><volume>18</volume> (<issue>4</issue>), <fpage>266</fpage>&#8211;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2017.138</pub-id><pub-id pub-id-type="pmid">29332936</pub-id><pub-id pub-id-type="pmcid">PMC7097228</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Snaith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cottingham</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A. V. s.</given-names></name></person-group> (<year>2017</year>). <article-title>Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine</article-title>. <source>Scientific Reports</source><volume>7</volume> (<issue>1</issue>). <pub-id pub-id-type="doi">10.1038/srep46621</pub-id><pub-id pub-id-type="pmcid">PMC5395940</pub-id><pub-id pub-id-type="pmid">28422178</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Commons</surname></name><name name-style="western"><surname>Robert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Simpson</surname></name><name name-style="western"><surname>Julie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thriemer</surname></name><name name-style="western"><surname>Kamala</surname></name><etal/></person-group> (<year>2019</year>). <article-title>The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis</article-title>. <source>PLOS MEDICINE</source><volume>16</volume>, <fpage>10</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1002928</pub-id><pub-id pub-id-type="pmcid">PMC6777759</pub-id><pub-id pub-id-type="pmid">31584960</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cowell</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Winzeler</surname><given-names>E. A.</given-names></name></person-group> (<year>2019</year>). <source>Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections</source>. <publisher-loc>London, United Kingdom</publisher-loc>: <publisher-name>BioMed Central Ltd.</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-019-0673-3</pub-id><pub-id pub-id-type="pmcid">PMC6805675</pub-id><pub-id pub-id-type="pmid">31640748</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cubides</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Camargo-Ayala</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Ni&#241;o</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Garz&#243;n-Ospina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ortega-Orteg&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ospina-Cantillo</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Simultaneous detection of Plasmodium vivax dhfr, dhps, mdr1 and crt-o resistance-associated mutations in the Colombian Amazonian region</article-title>. <source>Malar. J.</source><volume>17</volume>, <fpage>130</fpage>. <pub-id pub-id-type="doi">10.1186/s12936-018-2286-5</pub-id><pub-id pub-id-type="pmid">29580244</pub-id><pub-id pub-id-type="pmcid">PMC5870912</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Silva De Barros</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Portilho</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Dos Santos Matos</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Ricci-Junior</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alencar</surname><given-names>L. M. R.</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>C. C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Preliminary studies on drug delivery of polymeric primaquine microparticles using the liver high uptake effect based on size of particles to improve malaria treatment</article-title>. <source>Mat. Sci. Eng. C Mat. Biol. Appl.</source><volume>128</volume>, <fpage>112275</fpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2021.112275</pub-id><pub-id pub-id-type="pmid">34474834</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Silva Santos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Igne Ferreira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giarolla</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Dendrimer prodrugs</article-title>. <source>Molecules</source><volume>21</volume>, <fpage>686</fpage>. <pub-id pub-id-type="doi">10.3390/molecules21060686</pub-id><pub-id pub-id-type="pmcid">PMC6274429</pub-id><pub-id pub-id-type="pmid">27258239</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tripathy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pramanik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>A novel nano-anti-malarial induces redox damage and elicits cytokine response to the parasite</article-title>. <source>Cytokine</source><volume>144</volume>, <fpage>155555</fpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2021.155555</pub-id><pub-id pub-id-type="pmid">33992538</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dawre</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Enhanced antimalalarial activity of a prolonged release in situ gel of arteetherlumefantrine in a murine model</article-title>. <source>European Journal of Pharmaceutics and Biopharmaceutics</source><volume>123</volume>, <fpage>95107</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2017.11.002</pub-id><pub-id pub-id-type="pmid">29122736</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deda</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>E.</given-names></name><name name-style="western"><surname>Araki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>C. R. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Porphyrin derivative nanoformulations for therapy and antiparasitic agents</article-title>. <source>Molecules</source><volume>25</volume>, <fpage>20800</fpage>&#8211;<lpage>E2131</lpage>. <pub-id pub-id-type="doi">10.3390/molecules25092080</pub-id><pub-id pub-id-type="pmcid">PMC7249045</pub-id><pub-id pub-id-type="pmid">32365664</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dias</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Da Silva Santos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>J. V.</given-names></name><name name-style="western"><surname>Parise-Filho</surname><given-names>R.</given-names></name><name name-style="western"><surname>Igne Ferreira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seoud</surname><given-names>O. E.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Dendrimers in the context of nanomedicine</article-title>. <source>Int. J. Pharm.</source><volume>573</volume>, <fpage>118814</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118814</pub-id><pub-id pub-id-type="pmid">31759101</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dkhil</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Al-Shaebi</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Al-Quraishy</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Effect of indigofera oblongifolia on the hepatic oxidative status and expression of inflammatory and apoptotic genes during blood-stage murine malaria</article-title>. <source>Oxid. Med. Cell. Longev.</source><volume>2019</volume>, <fpage>8264861</fpage>. <pub-id pub-id-type="doi">10.1155/2019/8264861</pub-id><pub-id pub-id-type="pmid">30838089</pub-id><pub-id pub-id-type="pmcid">PMC6374864</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>
<italic toggle="yes">In vivo</italic> antimalarial activity and pharmacokinetics of artelinic acid-choline derivative liposomes in rodents</article-title>. <source>Parasitology</source><volume>147</volume>, <fpage>58</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1017/S0031182019001306</pub-id><pub-id pub-id-type="pmid">31556865</pub-id><pub-id pub-id-type="pmcid">PMC10317620</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunst</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kamena</surname><given-names>F.</given-names></name><name name-style="western"><surname>Matuschewski</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Cytokines and chemokines in cerebral malaria pathogenesis</article-title>. <source>Front. Cell. Infect. Microbiol.</source><volume>7</volume>, <fpage>324</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2017.00324</pub-id><pub-id pub-id-type="pmid">28775960</pub-id><pub-id pub-id-type="pmcid">PMC5517394</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ardestani</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Motevalian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hesari</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Hamzeh</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Antiplasmodial effect of nano dendrimer G2 loaded with chloroquine in mice infected with plasmodium berghei</article-title>. <source>Acta Parasitol.</source><volume>1</volume>, <fpage>298</fpage>&#8211;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1007/s11686-021-00459-4</pub-id><pub-id pub-id-type="pmid">34398379</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Markwalter</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prud'homme</surname><given-names>R. K.</given-names></name></person-group> (<year>2019</year>). <article-title>Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale</article-title>. <source>J. Transl. Med.</source><volume>17</volume>, <fpage>200</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-019-1945-9</pub-id><pub-id pub-id-type="pmid">31200738</pub-id><pub-id pub-id-type="pmcid">PMC6570894</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fotoran</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>M&#252;ntefering</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kleiber</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>B. N. M.</given-names></name><name name-style="western"><surname>Liebau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D. J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>A multilamellar nanoliposome stabilized by interlayer hydrogen bonds increases antimalarial drug efficacy</article-title>. <source>Nanomedicine</source><volume>22</volume>, <fpage>102099</fpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2019.102099</pub-id><pub-id pub-id-type="pmid">31648039</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frey</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Chelo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kinkela</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Djoukoue</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tietche</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hatz</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Artesunate-mefloquine combination therapy in acute plasmodium falciparum malaria in young children: A field study regarding neurological and neuropsychiatric safety</article-title>. <source>Malar. J.</source><volume>9</volume>, <fpage>291</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2875-9-291</pub-id><pub-id pub-id-type="pmid">20964849</pub-id><pub-id pub-id-type="pmcid">PMC2984569</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Mahant</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>D. N.</given-names></name></person-group> (<year>2020</year>). <article-title>Recent advancements in brain tumor targeting using magnetic nanoparticles</article-title>. <source>Ther. Deliv.</source><volume>11</volume>, <fpage>97</fpage>&#8211;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.4155/tde-2019-0077</pub-id><pub-id pub-id-type="pmid">31914859</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#233;rard Yam&#233;ogo</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Mazet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wouessidjewe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Choisnard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Godin-Ribuot</surname><given-names>D.</given-names></name><name name-style="western"><surname>Putaux</surname><given-names>J. L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Pharmacokinetic study of intravenously administered artemisinin-loaded surface-decorated amphiphilic &#947;-cyclodextrin nanoparticles</article-title>. <source>Mat. Sci. Eng. C Mat. Biol. Appl.</source><volume>106</volume>, <fpage>110281</fpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2019.110281</pub-id><pub-id pub-id-type="pmid">31753335</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Nanotized curcumin-benzothiophene conjugate: A potential combination for treatment of cerebral malaria</article-title>. <source>IUBMB Life</source><volume>72</volume>, <fpage>2637</fpage>&#8211;<lpage>2650</lpage>. <pub-id pub-id-type="doi">10.1002/iub.2394</pub-id><pub-id pub-id-type="pmid">33037778</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golenser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salaymeh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Higazi</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Alyan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daif</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dzikowski</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Treatment of experimental cerebral malaria by slow release of artemisone from injectable pasty formulation</article-title>. <source>Front. Pharmacol.</source><volume>11</volume>, <fpage>846</fpage>&#8211;<lpage>849</lpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00846</pub-id><pub-id pub-id-type="pmid">32595499</pub-id><pub-id pub-id-type="pmcid">PMC7303303</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Murine pharmacokinetics and antimalarial pharmacodynamics of dihydroartemisinin trimer self-assembled nanoparticles</article-title>. <source>Parasitol. Res.</source><volume>120</volume>, <fpage>2827</fpage>&#8211;<lpage>2837</lpage>. <pub-id pub-id-type="doi">10.1007/s00436-021-07208-6</pub-id><pub-id pub-id-type="pmid">34272998</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dogovski</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Dimeric artesunate-choline conjugate micelles coated with hyaluronic acid as a stable, safe and potent alternative anti-malarial injection of artesunate</article-title>. <source>Int. J. Pharm.</source><volume>609</volume>, <fpage>121138</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121138</pub-id><pub-id pub-id-type="pmid">34592395</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Transferrin conjugated ph-and redox-responsive poly(Amidoamine) dendrimer conjugate as an efficient drug delivery carrier for cancer therapy</article-title>. <source>International Journal of Nanomedicine</source><volume>15</volume>, <fpage>27512764</fpage>. <pub-id pub-id-type="doi">10.2147/IJN.S238536</pub-id><pub-id pub-id-type="pmcid">PMC7184127</pub-id><pub-id pub-id-type="pmid">32368053</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>M.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>). <article-title>Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria</article-title>. <source>Int. J. Pharm.</source><volume>562</volume>, <fpage>162</fpage>&#8211;<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.03.031</pub-id><pub-id pub-id-type="pmid">30902709</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaromin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parapini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Basilico</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zaremba-Czogalla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lewi&#324;ska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zag&#243;rska</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Azacarbazole n-3 and n-6 polyunsaturated fatty acids ethyl esters nanoemulsion with enhanced efficacy against Plasmodium falciparum</article-title>. <source>Bioact. Mat.</source><volume>6</volume>, <fpage>1163</fpage>&#8211;<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioactmat.2020.10.004</pub-id><pub-id pub-id-type="pmcid">PMC7588843</pub-id><pub-id pub-id-type="pmid">33134609</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jawahar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baruah</surname><given-names>U. K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>V.</given-names></name></person-group> (<year>2019</year>). <article-title>Co-delivery of chloroquine phosphate and azithromycin nanoparticles to overcome drug resistance in malaria through intracellular targeting</article-title>. <source>J. Pharm. Sci. Res.</source><volume>11</volume>, <fpage>33</fpage>&#8211;<lpage>40</lpage>. </mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kannan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Namdev</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lochab</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Pre-clinical study of iron oxide nanoparticles fortified artesunate for efficient targeting of malarial parasite</article-title>. <source>EBioMedicine</source><volume>45</volume>, <fpage>261</fpage>&#8211;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2019.06.026</pub-id><pub-id pub-id-type="pmid">31255656</pub-id><pub-id pub-id-type="pmcid">PMC6642363</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karunaweera</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Gamage</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mendis</surname><given-names>K. N.</given-names></name></person-group> (<year>1992</year>). <article-title>Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>89</volume>, <fpage>3200</fpage>&#8211;<lpage>3203</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.89.8.3200</pub-id><pub-id pub-id-type="pmid">1565611</pub-id><pub-id pub-id-type="pmcid">PMC48833</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashyap</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>U. K.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites</article-title>. <source>Int. J. Biol. Macromol.</source><volume>114</volume>, <fpage>161</fpage>&#8211;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.03.102</pub-id><pub-id pub-id-type="pmid">29572147</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kathpalia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Juvekar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohanraj</surname><given-names>K.</given-names></name><name name-style="western"><surname>Apsingekar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shidhaye</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Investigation of pre-clinical pharmacokinetic parameters of atovaquone nanosuspension prepared using a pH-based precipitation method and its pharmacodynamic properties in a novel artemisinin combination</article-title>. <source>J. Glob. Antimicrob. Resist.</source><volume>22</volume>, <fpage>248</fpage>&#8211;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgar.2020.02.018</pub-id><pub-id pub-id-type="pmid">32119990</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Katsoulis</surname><given-names>O.</given-names></name><name name-style="western"><surname>Georgiadou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cunnington</surname><given-names>A. J.</given-names></name></person-group> (<year>2021</year>). <source>Immunopathology of acute kidney injury in severe malaria</source>. <publisher-loc>Lausanne, Switzerland</publisher-loc>: <publisher-name>Frontiers Media SA</publisher-name>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.651739</pub-id><pub-id pub-id-type="pmcid">PMC8102819</pub-id><pub-id pub-id-type="pmid">33968051</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gorki</surname><given-names>V.</given-names></name><name name-style="western"><surname>Katare</surname><given-names>O. P.</given-names></name><name name-style="western"><surname>Dhingra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system: Preclinical investigation on NK-65 P.berghei murine model</article-title>. <source>Expert Opin. Drug Deliv.</source><volume>18</volume>, <fpage>1533</fpage>&#8211;<lpage>1552</lpage>. <pub-id pub-id-type="doi">10.1080/17425247.2021.1946512</pub-id><pub-id pub-id-type="pmid">34176411</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinkhamhom</surname><given-names>A.</given-names></name><name name-style="western"><surname>Glaharn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Srisook</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ampawong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krudsood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>S. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>M1 macrophage features in severe Plasmodium falciparum malaria patients with pulmonary oedema</article-title>. <source>Malar. J.</source><volume>19</volume>, <fpage>182</fpage>. <pub-id pub-id-type="doi">10.1186/s12936-020-03254-0</pub-id><pub-id pub-id-type="pmid">32414377</pub-id><pub-id pub-id-type="pmcid">PMC7226720</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knackstedt</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Georgiadou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Apel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abu-Abed</surname><given-names>U.</given-names></name><name name-style="western"><surname>Moxon</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Cunnington</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Neutrophil extracellular traps drive inflammatory pathogenesis in malaria</article-title>. <source>Sci. Immunol.</source><volume>4</volume>, <fpage>eaaw0336</fpage>&#8211;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.aaw0336</pub-id><pub-id pub-id-type="pmid">31628160</pub-id><pub-id pub-id-type="pmcid">PMC6892640</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Angov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N.</given-names></name></person-group> (<year>2015</year>). <article-title>Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles</article-title>. <source>Vaccine</source><volume>33</volume>, <fpage>5064</fpage>&#8211;<lpage>5071</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.025</pub-id><pub-id pub-id-type="pmid">26299750</pub-id><pub-id pub-id-type="pmcid">PMC4577455</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L-Quraishay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murshed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Al-Shaebi</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Qasem</surname><given-names>M. a. A.</given-names></name><name name-style="western"><surname>Mares</surname><given-names>M. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Plasmodium chabaudi-infected mice spleen response to synthesized silver nanoparticles from Indigofera oblongifolia extract</article-title>. <source>Lett. Appl. Microbiol.</source><volume>71</volume>, <fpage>542</fpage>&#8211;<lpage>549</lpage>. <pub-id pub-id-type="doi">10.1111/lam.13366</pub-id><pub-id pub-id-type="pmid">32749003</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhav</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoda</surname><given-names>N.</given-names></name></person-group> (<year>2021</year>). <article-title>An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins</article-title>. <source>Eur. J. Med. Chem.</source><volume>210</volume>, <fpage>112955</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112955</pub-id><pub-id pub-id-type="pmid">33131885</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manconi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Manca</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Escribano-Ferrer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Coma-Cros</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Biosca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lantero</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Nanoformulation of curcumin-loaded eudragit-nutriosomes to counteract malaria infection by a dual strategy: Improving antioxidant intestinal activity and systemic efficacy</article-title>. <source>Int. J. Pharm.</source><volume>556</volume>, <fpage>82</fpage>&#8211;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.11.073</pub-id><pub-id pub-id-type="pmid">30528634</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237; Coma-Cros</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lancelot</surname><given-names>A.</given-names></name><name name-style="western"><surname>San Anselmo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neves Borgheti-Cardoso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valle-Delgado</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>J. L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Micelle carriers based on dendritic macromolecules containing bis-MPA and glycine for antimalarial drug delivery</article-title>. <source>Biomater. Sci.</source><volume>7</volume>, <fpage>1661</fpage>&#8211;<lpage>1674</lpage>. <pub-id pub-id-type="doi">10.1039/c8bm01600c</pub-id><pub-id pub-id-type="pmid">30741274</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marwah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Narain Srivastava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagarsenker</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Functionally engineered &#8216;hepato-liposomes&#8217;: Combating liver-stage malaria in a single prophylactic dose</article-title>. <source>Int. J. Pharm.</source><volume>587</volume>, <fpage>119710</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119710</pub-id><pub-id pub-id-type="pmid">32739383</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dondorp</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Antimalarial drug resistance: A threat to malaria elimination</article-title>. <source>Cold Spring Harb. Perspect. Med.</source><volume>7</volume>, <fpage>a025619</fpage>&#8211;<lpage>a025624</lpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a025619</pub-id><pub-id pub-id-type="pmid">28289248</pub-id><pub-id pub-id-type="pmcid">PMC5495053</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metwally</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Alajmi</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>El-Khadragy</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Al-Quraishy</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Silver nanoparticles biosynthesized with Salvia officinalis leaf exert protective effect on hepatic tissue injury induced by plasmodium chabaudi</article-title>. <source>Front. Vet. Sci.</source><volume>7</volume>, <fpage>620665</fpage>. <pub-id pub-id-type="doi">10.3389/fvets.2020.620665</pub-id><pub-id pub-id-type="pmid">33614756</pub-id><pub-id pub-id-type="pmcid">PMC7889953</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miatmoko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nurjannah</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nehru</surname><given-names>N. F.</given-names></name><name name-style="western"><surname>Rosita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hendradi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sari</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>12420</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-91866-0</pub-id><pub-id pub-id-type="pmid">34127730</pub-id><pub-id pub-id-type="pmcid">PMC8203617</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michels</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Maciel</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Nakama</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>F. E. G.</given-names></name><name name-style="western"><surname>De Carvalho</surname><given-names>F. B.</given-names></name><name name-style="western"><surname>Gundel</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Effects of surface characteristics of polymeric nanocapsules on the pharmacokinetics and efficacy of antimalarial quinine</article-title>. <source>Int. J. Nanomedicine</source><volume>14</volume>, <fpage>10165</fpage>&#8211;<lpage>10178</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S227914</pub-id><pub-id pub-id-type="pmid">32021159</pub-id><pub-id pub-id-type="pmcid">PMC6942527</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milner</surname><given-names>D. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Malaria pathogenesis</article-title>. <source>Cold Spring Harb. Perspect. Med.</source><volume>8</volume>, <fpage>a025569</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a025569</pub-id><pub-id pub-id-type="pmid">28533315</pub-id><pub-id pub-id-type="pmcid">PMC5749143</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Haley</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Peppas</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Engineering precision nanoparticles for drug delivery</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>20</volume>, <fpage>101</fpage>&#8211;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreira Souza</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Grabe-Guimar&#227;es</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>J. D. S.</given-names></name><name name-style="western"><surname>Santos-Miranda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farah</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teixeira Oliveira</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation</article-title>. <source>Br. J. Pharmacol.</source><volume>177</volume>, <fpage>4448</fpage>&#8211;<lpage>4463</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15186</pub-id><pub-id pub-id-type="pmid">32608017</pub-id><pub-id pub-id-type="pmcid">PMC7484510</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moxon</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Gibbins</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Mcguinness</surname><given-names>D.</given-names></name><name name-style="western"><surname>Milner</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Marti</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>New insights into malaria pathogenesis</article-title>. <source>Annu. Rev. Pathol.</source><volume>15</volume>, <fpage>315</fpage>&#8211;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012419-032640</pub-id><pub-id pub-id-type="pmid">31648610</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mugumbate</surname><given-names>G.</given-names></name><name name-style="western"><surname>Eloff</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Louw</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Maharaj</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Birkholtz</surname><given-names>L. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Natural products: A potential source of malaria transmission blocking drugs?</article-title><source>Pharmaceuticals (Basel)</source><volume>13</volume>(<issue>9</issue> ), <fpage>251</fpage>. <pub-id pub-id-type="doi">10.3390/ph13090251</pub-id><pub-id pub-id-type="pmcid">PMC7558993</pub-id><pub-id pub-id-type="pmid">32957668</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mubaraki</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Hafiz</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Al-Quraishy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dkhil</surname><given-names>M. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Oxidative stress and genes regulation of cerebral malaria upon Zizyphus spina-christi treatment in a murine model</article-title>. <source>Microb. Pathog.</source><volume>107</volume>, <fpage>69</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2017.03.017</pub-id><pub-id pub-id-type="pmid">28336326</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Najer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Palivan</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>H. P.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>W.</given-names></name></person-group> (<year>2018</year>). <source>Challenges in malaria management and a glimpse at some nanotechnological approaches</source>. <publisher-loc>Singapore</publisher-loc>: <publisher-name>Springer Singapore</publisher-name>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-10-7572-8_9</pub-id><pub-id pub-id-type="pmid">29785484</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nawwab al-deen</surname><given-names>F. M.</given-names></name></person-group> (<year>2017</year>). <source>Magnetic nanovectors for the development of DNA blood-stage malaria vaccines</source><volume>7</volume> (<issue>2</issue>), <fpage>10</fpage>. <pub-id pub-id-type="doi">10.3390/nano7020030</pub-id><pub-id pub-id-type="pmcid">PMC5333015</pub-id><pub-id pub-id-type="pmid">28336871</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neves Borgheti-Cardoso</surname><given-names>L.</given-names></name><name name-style="western"><surname>San Anselmo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lantero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lancelot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Ainsa</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Promising nanomaterials in the fight against malaria</article-title>. <source>J. Mat. Chem. B</source><volume>8</volume>, <fpage>9428</fpage>&#8211;<lpage>9448</lpage>. <pub-id pub-id-type="doi">10.1039/d0tb01398f</pub-id><pub-id pub-id-type="pmid">32955067</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nnamani</surname><given-names>P. O.</given-names></name><name name-style="western"><surname>Ugwu</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Nnadi</surname><given-names>O. H.</given-names></name><name name-style="western"><surname>Kenechukwu</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>KennethOfokansi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Attama</surname><given-names>A. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Formulation and evaluation of transdermal nanogel for delivery of artemether</article-title>. <source>Drug Deliv. Transl. Res.</source><volume>1</volume>, <fpage>1655</fpage>&#8211;<lpage>1674</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-021-00951-4</pub-id><pub-id pub-id-type="pmid">33742415</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nosrati</surname><given-names>H.</given-names></name><name name-style="western"><surname>Salehiabar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bagheri</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rashidzadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Davaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Danafar</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>Preparation, characterization, and evaluation of amino acid modified magnetic nanoparticles: Drug delivery and MRI contrast agent applications</article-title>. <source>Pharm. Dev. Technol.</source><volume>23</volume>, <fpage>1156</fpage>&#8211;<lpage>1167</lpage>. <pub-id pub-id-type="doi">10.1080/10837450.2018.1536995</pub-id><pub-id pub-id-type="pmid">30320535</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novitt-Moreno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martidis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ransom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Dow</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen: A 12-month, randomized, double-blind, placebo-controlled trial</article-title>. <source>Travel Med. Infect. Dis.</source><volume>45</volume>, <fpage>102211</fpage>. <pub-id pub-id-type="doi">10.1016/j.tmaid.2021.102211</pub-id><pub-id pub-id-type="pmid">34801714</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nsanzabana</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>Tropical medicine and infectious disease resistance to artemisinin combination therapies (ACTs): Do not forget the partner drug!</article-title>. <source>Trop. Med. Infect. Dis.</source><volume>4</volume> (<issue>1</issue>), <fpage>26</fpage>. <pub-id pub-id-type="doi">10.3390/tropicalmed4010026</pub-id><pub-id pub-id-type="pmcid">PMC6473515</pub-id><pub-id pub-id-type="pmid">30717149</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obonyo</surname><given-names>C. O.</given-names></name><name name-style="western"><surname>Juma</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Were</surname><given-names>V. O.</given-names></name><name name-style="western"><surname>Ogutu</surname><given-names>B. R.</given-names></name></person-group> (<year>2022</year>). <article-title>Efficacy of 3-day low dose quinine plus clindamycin versus artemether-lumefantrine for the treatment of uncomplicated plasmodium falciparum malaria in Kenyan children (CLINDAQUINE): An open-label randomized trial</article-title>. <source>Malar. J.</source><volume>21</volume>, <fpage>30</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1186/s12936-022-04050-8</pub-id><pub-id pub-id-type="pmid">35109841</pub-id><pub-id pub-id-type="pmcid">PMC8809037</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owonubi</surname><given-names>S. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Characterization and in vitro release kinetics of antimalarials from whey protein-based hydrogel biocomposites</article-title>. <source>International Journal of Industrial Chemistry</source><volume>9</volume> (<issue>1</issue>), <fpage>3952</fpage>. <pub-id pub-id-type="doi">10.1007/s40090-018-0139-2</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oyelade</surname><given-names>J.</given-names></name><name name-style="western"><surname>Isewon</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aromolaran</surname><given-names>O.</given-names></name><name name-style="western"><surname>Uwoghiren</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dokunmu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rotimi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Computational identification of metabolic pathways of plasmodium falciparum using the k-shortest path algorithm</article-title>. <source>Int. J. Genomics</source><volume>2019</volume>, <fpage>1750291</fpage>. <pub-id pub-id-type="doi">10.1155/2019/1750291</pub-id><pub-id pub-id-type="pmid">31662957</pub-id><pub-id pub-id-type="pmcid">PMC6791207</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panzarini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mariano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carata</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mura</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dini</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Intracellular transport of silver and gold nanoparticles and biological responses: An update</article-title>. <source>Int. J. Mol. Sci.</source><volume>19</volume> (<issue>5</issue>), <fpage>1305</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19051305</pub-id><pub-id pub-id-type="pmcid">PMC5983807</pub-id><pub-id pub-id-type="pmid">29702561</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bharti</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Mohapatra</surname><given-names>P. K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Prevalence of mutations linked to antimalarial resistance in plasmodium falciparum from Chhattisgarh, central India: A malaria elimination point of view</article-title>. <source>Sci. Rep.</source><volume>7</volume>, <fpage>16690</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-16866-5</pub-id><pub-id pub-id-type="pmid">29192183</pub-id><pub-id pub-id-type="pmcid">PMC5709362</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pestehchian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vafaei</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Nematolahy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Varshosaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Bide</surname><given-names>V. Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A new effective antiplasmodial compound: Nanoformulated pyrimethamine</article-title>. <source>J. Glob. Antimicrob. Resist.</source><volume>20</volume>, <fpage>309</fpage>&#8211;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgar.2019.08.002</pub-id><pub-id pub-id-type="pmid">31404680</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Manyando</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van Huijsduijnen</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Van Voorhis</surname><given-names>W. C.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>T. N. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Malaria</article-title>. <source>Nat. Rev. Dis. Prim.</source><volume>3</volume>, <fpage>17050</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2017.50</pub-id><pub-id pub-id-type="pmid">28770814</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powles</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Selomulya</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Pullulan-Coated Iron Oxide Nanoparticles for Blood-Stage Malaria Vaccine Delivery</article-title>. <source>Vaccines</source><volume>8</volume> (<issue>4</issue>), <fpage>651</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines8040651</pub-id><pub-id pub-id-type="pmcid">PMC7711541</pub-id><pub-id pub-id-type="pmid">33153189</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puttappa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Kuppusamy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Nano-facilitated drug delivery strategies in the treatment of plasmodium infection</article-title>. <source>Acta Trop.</source><volume>195</volume>, <fpage>103</fpage>&#8211;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.actatropica.2019.04.020</pub-id><pub-id pub-id-type="pmid">31039335</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Rai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paralikar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jogee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Agarkar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ingle</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Derita</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <source>Synergistic antimicrobial potential of essential oils in combination with nanoparticles: Emerging trends and future perspectives</source>. <publisher-loc>Amsterdam, Netherlands</publisher-loc>: <publisher-name>Elsevier B.V</publisher-name>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2017.01.013</pub-id><pub-id pub-id-type="pmid">28089935</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramazani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keramati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Malvandi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Danafar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kheiri Manjili</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>Preparation and <italic toggle="yes">in vivo</italic> evaluation of anti-plasmodial properties of artemisinin-loaded PCL&#8211;PEG&#8211;PCL nanoparticles</article-title>. <source>Pharm. Dev. Technol.</source><volume>23</volume>, <fpage>911</fpage>&#8211;<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1080/10837450.2017.1372781</pub-id><pub-id pub-id-type="pmid">28851256</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rashidzadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Salimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sadighian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rostamizadeh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ramazani</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>
<italic toggle="yes">In vivo</italic> antiplasmodial activity of curcumin-loaded nanostructured lipid carriers</article-title>. <source>Curr. Drug Deliv.</source><volume>16</volume>, <fpage>923</fpage>&#8211;<lpage>930</lpage>. <pub-id pub-id-type="doi">10.2174/1567201816666191029121036</pub-id><pub-id pub-id-type="pmid">31663477</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rashidzadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tabatabaei Rezaei</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Adyani</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Abazari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahamooz Haghighi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abdollahi</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Recent advances in targeting malaria with nanotechnology-based drug carriers</article-title>. <source>Pharm. Dev. Technol.</source><volume>26</volume>, <fpage>807</fpage>&#8211;<lpage>823</lpage>. <pub-id pub-id-type="doi">10.1080/10837450.2021.1948568</pub-id><pub-id pub-id-type="pmid">34190000</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="book"><collab>Report on antimalarial drug efficacy</collab> (<year>2020</year>). <source>Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019)</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>. </mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ristroph</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mcmanus</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ramachandruni</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Spray drying OZ439 nanoparticles to form stable, water-dispersible powders for oral malaria therapy</article-title>. <source>J. Transl. Med.</source><volume>17</volume>, <fpage>97</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-019-1849-8</pub-id><pub-id pub-id-type="pmid">30902103</pub-id><pub-id pub-id-type="pmcid">PMC6431012</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Dhingra</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wicht</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>K&#252;mpornsin</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine</article-title>. <source>Nat. Commun.</source><volume>9</volume>, <fpage>3314</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-05652-0</pub-id><pub-id pub-id-type="pmid">30115924</pub-id><pub-id pub-id-type="pmcid">PMC6095916</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grillaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Elucidation of the cellular uptake mechanisms of polycationic HYDRAmers</article-title>. <source>Bioconjug. Chem.</source><volume>26</volume>, <fpage>1484</fpage>&#8211;<lpage>1493</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.5b00270</pub-id><pub-id pub-id-type="pmid">26046960</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahoo</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation</article-title>. <source>International Journal of Pharmaceutics</source><volume>584</volume>, <fpage>119389</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119389</pub-id><pub-id pub-id-type="pmid">32380027</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Murshed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clulow</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Impact of ferroquine on the solubilization of artefenomel (OZ439) during <italic toggle="yes">in vitro</italic> lipolysis in milk and implications for oral combination therapy for malaria</article-title>. <source>Mol. Pharm.</source><volume>16</volume>, <fpage>1658</fpage>&#8211;<lpage>1668</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b01333</pub-id><pub-id pub-id-type="pmid">30830789</pub-id><pub-id pub-id-type="pmcid">PMC6448114</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherje</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dravyakar</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Kadam</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>Dendrimers: A versatile nanocarrier for drug delivery and targeting</article-title>. <source>Int. J. Pharm.</source><volume>548</volume>, <fpage>707</fpage>&#8211;<lpage>720</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.07.030</pub-id><pub-id pub-id-type="pmid">30012508</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>M. G. D.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Perasoli</surname><given-names>F. B.</given-names></name><name name-style="western"><surname>Branquinho</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Mourao</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>H. D. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nanoemulsion composed of 10-(4, 5-dihydrothiazol-2-yl)thio)decan-1-ol), a synthetic analog of 3-alkylpiridine marine alkaloid: Development, characterization, and antimalarial activity</article-title>. <source>Eur. J. Pharm. Sci.</source><volume>151</volume>, <fpage>105382</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2020.105382</pub-id><pub-id pub-id-type="pmid">32470575</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Souza Botelho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bolfi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>R. G. O. F.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>M. S. F.</given-names></name><name name-style="western"><surname>Banzato</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>L. T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions</article-title>. <source>Syst. Rev.</source><volume>10</volume>, <fpage>294</fpage>&#8211;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1186/s13643-021-01835-x</pub-id><pub-id pub-id-type="pmid">34736537</pub-id><pub-id pub-id-type="pmcid">PMC8567984</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staines</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Burrow</surname><given-names>R.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>B. H. Y.</given-names></name><name name-style="western"><surname>Ster</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Kremsner</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Clinical implications of plasmodium resistance to atovaquone/proguanil: A systematic review and meta-analysis</article-title>. <source>J. Antimicrob. Chemother.</source><volume>73</volume> (<issue>3</issue>), <fpage>581</fpage>&#8211;<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkx431</pub-id><pub-id pub-id-type="pmid">29237012</pub-id><pub-id pub-id-type="pmcid">PMC5890752</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Summers</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Pasaje</surname><given-names>C. F. A.</given-names></name><name name-style="western"><surname>Pisco</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Striepen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luth</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Kumpornsin</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention</article-title>. <source>Cell Chem. Biol.</source><volume>29</volume>, <fpage>191</fpage>&#8211;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2021.07.010</pub-id><pub-id pub-id-type="pmid">34348113</pub-id><pub-id pub-id-type="pmcid">PMC8878317</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talman</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Clain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duval</surname><given-names>R.</given-names></name><name name-style="western"><surname>M&#233;nard</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ariey</surname><given-names>F.</given-names></name></person-group> (<year>2019</year>). <article-title>Artemisinin bioactivity and resistance in malaria parasites</article-title>. <source>Trends Parasitol.</source><volume>35</volume>, <fpage>953</fpage>&#8211;<lpage>963</lpage>. <pub-id pub-id-type="doi">10.1016/j.pt.2019.09.005</pub-id><pub-id pub-id-type="pmid">31699532</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thriemer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bobogare</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dysoley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Pasaribu</surname><given-names>A. P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Challenges for achieving safe and effective radical cure of plasmodium vivax: A round table discussion of the APMEN vivax working group</article-title>. <source>Malar. J.</source><volume>16</volume>, <fpage>141</fpage>. <pub-id pub-id-type="doi">10.1186/s12936-017-1784-1</pub-id><pub-id pub-id-type="pmid">28381261</pub-id><pub-id pub-id-type="pmcid">PMC5382417</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toure</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Valecha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tshefu</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Krudsood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gaye</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>A phase 3, double-blind, randomized study of arterolane maleate-piperaquine phosphate vs artemether-lumefantrine for falciparum malaria in adolescent and adult patients in asia and africa</article-title>. <source>Clin. Infect. Dis.</source><volume>62</volume>, <fpage>964</fpage>&#8211;<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciw029</pub-id><pub-id pub-id-type="pmid">26908796</pub-id><pub-id pub-id-type="pmcid">PMC4803108</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tse</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Korsik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>M. H.</given-names></name></person-group> (<year>2019</year>). <article-title>The past, present and future of anti-malarial medicines</article-title>. <source>Malar. J.</source><volume>18</volume> (<issue>1</issue>), <fpage>93</fpage>. <pub-id pub-id-type="doi">10.1186/s12936-019-2724-z</pub-id><pub-id pub-id-type="pmid">30902052</pub-id><pub-id pub-id-type="pmcid">PMC6431062</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umeyor</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Obachie</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chukwuka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Attama</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Development insights of surface modified lipid nanoemulsions of dihydroartemisinin for malaria chemotherapy: Characterization, and <italic toggle="yes">in vivo</italic> antimalarial evaluation</article-title>. <source>Recent Pat. Biotechnol.</source><volume>13</volume>, <fpage>149</fpage>&#8211;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.2174/1872208313666181204095314</pub-id><pub-id pub-id-type="pmid">30514197</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varela-Aramburu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goerdeler</surname><given-names>F.</given-names></name><name name-style="western"><surname>Priegue</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moscovitz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Targeting and inhibiting plasmodium falciparum using ultra-small gold nanoparticles</article-title>. <source>ACS Appl. Mat. Interfaces</source><volume>12</volume>, <fpage>43380</fpage>&#8211;<lpage>43387</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.0c09075</pub-id><pub-id pub-id-type="pmcid">PMC7586288</pub-id><pub-id pub-id-type="pmid">32875786</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpe-Zanutto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>L. T.</given-names></name><name name-style="western"><surname>Permana</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Kirkby</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>L. K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Artemether and lumefantrine dissolving microneedle patches with improved pharmacokinetic performance and antimalarial efficacy in mice infected with Plasmodium yoelii</article-title>. <source>J. Control. Release</source><volume>333</volume>, <fpage>298</fpage>&#8211;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.03.036</pub-id><pub-id pub-id-type="pmid">33794272</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Enhanced antimalarial efficacy obtained by targeted delivery of artemisinin in heparin-coated magnetic hollow mesoporous nanoparticles</article-title>. <source>ACS Appl. Mat. Interfaces</source><volume>13</volume>, <fpage>287</fpage>&#8211;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.0c20070</pub-id><pub-id pub-id-type="pmid">33356111</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Who</surname></name></person-group> (<year>2019</year>). <article-title>World malaria report 2019</article-title>. <source>Avaiable at:</source><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/iris/handle/10665/330011" ext-link-type="uri">https://apps.who.int/iris/handle/10665/330011</ext-link>.Accessed 4 December 2019.</comment></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>World malaria report</surname></name></person-group> (<year>2021</year>). <source>World malaria report 2021</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>. </mixed-citation></ref><ref id="B116"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Who</surname></name></person-group> (<year>2015</year>). <source>Guidelines for the treatment of malaria</source>. <edition>3rd edition</edition>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <fpage>299</fpage>. </mixed-citation></ref><ref id="B117"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>World malaria report</surname></name></person-group> (<year>2020</year>). <source>World malaria report 2020: 20 years of global progress and challenges</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>. </mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wicht</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fidock</surname><given-names>D. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Molecular mechanisms of drug resistance in plasmodium falciparum malaria</article-title>. <source>Annu. Rev. Microbiol.</source><volume>74</volume>, <fpage>431</fpage>&#8211;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115546</pub-id><pub-id pub-id-type="pmid">32905757</pub-id><pub-id pub-id-type="pmcid">PMC8130186</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Pouniotis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R. L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>A synthetic nanoparticle based vaccine approach targeting MSP4/5 is immunogenic and induces moderate protection against murine blood-stage malaria</article-title>. <source>Front. Immunol.</source><volume>10</volume>, <fpage>331</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00331</pub-id><pub-id pub-id-type="pmid">30930890</pub-id><pub-id pub-id-type="pmcid">PMC6428706</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dudhipala</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lakhani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chaurasiya</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Tekwani</surname><given-names>B. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Primaquine loaded solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nanoemulsion (NE): Effect of lipid Matrix and surfactant on drug entrapment, <italic toggle="yes">in vitro</italic> release, and <italic toggle="yes">ex vivo</italic> hemolysis</article-title>. <source>AAPS PharmSciTech</source><volume>22</volume>, <fpage>240</fpage>. <pub-id pub-id-type="doi">10.1208/s12249-021-02108-5</pub-id><pub-id pub-id-type="pmid">34590195</pub-id><pub-id pub-id-type="pmcid">PMC9178661</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><collab>WWARN K13 Genotype-Phenotype Study Group</collab> (<year>2021</year>). <article-title>Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis</article-title>. <source>BMC medicine</source><volume>17</volume>, <fpage>11</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-018-1207-3</pub-id><pub-id pub-id-type="pmcid">PMC6335805</pub-id><pub-id pub-id-type="pmid">30651111</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Surveillance of antimalarial resistance Pfcrt, Pfmdr1, and Pfkelch13 polymorphisms in african plasmodium falciparum imported to shandong province, China</article-title>. <source>Sci. Rep.</source><volume>8</volume> (<issue>1</issue>), <fpage>1</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-31207-w</pub-id><pub-id pub-id-type="pmid">30154519</pub-id><pub-id pub-id-type="pmcid">PMC6113250</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yahiya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rueda-Zubiaurre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Delves</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Fuchter</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>The antimalarial screening landscape&#8212;Looking beyond the asexual blood stage</article-title>. <source>Curr. Opin. Chem. Biol.</source><volume>50</volume>, <fpage>1</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2019.01.029</pub-id><pub-id pub-id-type="pmid">30875617</pub-id><pub-id pub-id-type="pmcid">PMC6591700</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lakshmi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Efficacy and safety of a naphthoquine-azithromycin coformulation for malaria prophylaxis in southeast asia: A phase 3, double-blind, randomized, placebo-controlled trial</article-title>. <source>Clin. Infect. Dis.</source><volume>73</volume>, <fpage>e2470</fpage>&#8211;<lpage>e2476</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa1018</pub-id><pub-id pub-id-type="pmid">32687174</pub-id><pub-id pub-id-type="pmcid">PMC8492115</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Han</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Neglected interstitial space in malaria recurrence and treatment</article-title>. <source>Nano Res.</source><volume>13</volume> (<issue>10</issue>), <fpage>2869</fpage>&#8211;<lpage>2878</lpage>. <pub-id pub-id-type="doi">10.1007/s12274-020-2946-y</pub-id><pub-id pub-id-type="pmid">32837694</pub-id><pub-id pub-id-type="pmcid">PMC7378403</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>